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The dopamine transporter (DAT) is responsible for the removal of the neurotransmitter 
from the synaptic gap and a therapeutic target for a multitude of drugs. While the ortholog 
Drosophila melanogaster dopamine transporter (dDAT) and human serotonin transporter 
(hSERT) have resolved structures, the human dopamine transporter (hDAT) does not. A 
3-D computational homology model of hDAT was constructed for the study of molecular 




Synthetic cathiones are a class of abused stimulant drugs that primarily target DAT. 
Greater than 150 cathinones have been identified on the clandestine market but there is 
not much known about the structure-activity relationship (SAR) of these abused 
compounds. A dichloro substituted benzoylpiperdine compound, part of novel series of 
benzoylpiperdine cathinones, was found to be a potent DAT inhibitor. Two new 
disubstituted compounds were computationally modelled, synthesized, and biologically 
evaluated to investigate the effect of these substituents in DAT inhibitor potency. It was 
found that all compounds were active and that the hybrids with electron donating 
substituents were weaker compared to the hybrids with electron withdrawing substituents 
tested.   
 
Cathinones based on the pyrrolidinophenone scaffold, such as 3,4-
methylenedioxypyrovalerone (MDPV), -pyrrolidinopentiophenone (-PVP), and 3,4-
methylenedioxy--pyrrolidinopropiophenone (MDPPP), are established illicit 
psychostimulants. These compounds are potent inhibitors of hDAT but have little to no 
activity at dDAT. In collaboration with Dr. Eltit’s lab (VCU) gain-of-function studies and in 
silico modeling using mutant DAT transporters were performed. Four non-conserved 
amino acid residues critical for MDPV’s high potency activity as a reuptake inhibitor at 
hDAT were identified. These residues can drive MDPV selectivity not only by stabilizing 




Monoamine transporters (MATs) are a family of transporters that regulate the 
concentration of neurotransmitters in the synaptic gap.1 Dysfunction of these transporters 
are responsible for a number of neuropsychiatric disorders.1 MATs are a target for 
therapeutic agents that can treat these disorders but is also a primary target for drugs of 
abuse.1 Of the three MATs, the dopamine transporter (DAT) is a specific target of abused 
stimulant drugs due to dopamine’s (DA) reward pathways.1 
 
Human DAT (hDAT) does not have a solved crystal structure therefore computational 
modelling studies of this transporter must make use of homology models.  Less than 20 
years ago the bacterial ortholog leucine transporter had been crystallized and was 
essential for the first developed homology models for hDAT.2 Even more recently 
drosophila DAT dDAT had been crystallized followed by hSERT.3,4 With the newer, more 
closely related crystallized transporter structures available, a more accurate homology 
model will be developed to conduct molecular modeling studies of hDAT. 
 
Synthetic cathinones are a vast class of stimulant compounds structurally related to the 
naturally occurring stimulant cathinone found in the leaves of the khat plant.5 This group 
of compounds is responsible for the majority of stimulant new psychoactive substances 
(NPS) and more are emerging every year on the clandestine market.5 While there are 
numerous cathinones that are being abused, little is known about the SAR of these 
compounds. Methylphenidate which is a well-known and prescribed drug for attention 
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deficit hyperactivity disorder (ADHD) has extensive SAR established.6 Efforts have 
successfully been made to correlate a novel series of benzoylpiperdine cathinones that 
share features with methylphenidate with known methylphenidate analogs in order to use 
the known methylphenidate SAR to inform cathinone SAR.7 In this series, it was found 
that the 3,4-dichloro substituted benzoylpiperdine was the most potent, even more potent 
than methylphenidate.7 To expand on SAR understanding of hDAT and to determine 
which aspects cause the high potency of this disubstituted compound, two new 
benzoylpiperdine compounds with varying electronic and lipophilic character will be 
prepared and studied. 
 
dDAT, which can be considered a hDAT mutant, functions the same under normal 
conditions. Abused stimulant cathinones such as MDPV are highly active at hDAT but 
have little to no activity at dDAT. These two transporters are closely related and share 
over 50% sequence identity.3 In collaboration with Dr. Eltit’s lab, a series of mutant dDATs 
were studied and it was found that with only 4 point mutations of dDAT to hDAT amino 
acid residues, MDPV gained activity in the mutant dDAT similar to what is observed in 
hDAT. Modelling will be performed in order to determine which amino acids are important 
in these interactions and what the cause of gain-of-function is for the mutant. 
 
Utilizing this two pronged approach where hDAT will be studied using new compounds 
(cathinone hybrids) as well as using new transporters (dDAT mutants), a better 
understanding of the innerworkings of hDAT can be established which is essential for the 
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development of new medications for psychostimulant dependence, attention deficit 





















A. Monoamine Transporters (MATs) 
The biogenic amine (monoamine) transporters or MATs are part of the neurotransmitter 
sodium symporter (NSS) and solute carrier 6 (SLC6) family.1 They are a 12 
transmembrane helix protein (Figure 1) that are Na+/Cl- dependent.1 These transporters 
are found on neurons and glial cells, and are responsible for regulation of synaptic 
monoamines (serotonin (5-HT), dopamine (DA), and norepinephrine (NE)) that activate 










Figure 1. Topology of monoamine transporters depicting 12 transmembrane domains 






Regulation occurs by the use of an electrochemical gradient to actively remove the 
monoamines from the extracellular space back into the presynaptic neuron through the 
transporter.1 A different transporter is primarily responsible for each corresponding 
monoamine.11 SERT is responsible for 5-HT (1), NET for NE (2), and DAT for DA (3) 
(Figure 2).11 Each transporter moves the appropriate neurotransmitter along with different 
molar equivalent ions.1 NET uses one Na+ ion and one Cl- ion. DAT uses two Na+ ions 
and one Cl- ion. SERT uses one Na+ ion, one Cl- ion, and counter transports one K+ ion.1 
The intercellular potassium ion is transported to the extracellular space after the ligands 
(5-HT, Na+, and Cl-) have been released intercellularly and the transporter is changing 




Figure 2. A) Schematic representation of monoaminergic synaptic terminals. B) Chemical 
structures of the endogenous substrates for SLC6 neurotransmitter transporters (NTTs) 
and ion coupling stoichiometry for neurotransmitter reuptake.13  
 
These transporters play a role in neuropsychiatric disorders such as attention deficit 
hyperactivity disorder (ADHD), depression, orthostatic intolerance, epilepsy, 
Parkinsonism, schizophrenia, and drug abuse.1 In 1961, Hertting and Axelrod were the 
first to describe the concept of the reuptake of NE (2) by sympathetic nerve terminals.8 It 
was postulated that the reuptake of neurotransmitters by a transporter was essential for 
their deactivation.8 DA and 5-HT were also later shown to have similar mechanisms.10 
Countless studies have since been conducted on the function of the monoamine uptake 
transporters. By the 1990s, the genes that code for the monoamine transporter proteins 
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were determined due to progress in molecular cloning techniques.14 This facilitated the 
discovery of the localization, structural and functional domains, and contributions to brain 
function of the transporters using a variety of techniques such as heterologous expression 
systems, mutagenesis, in vivo imaging, and animal models with disrupted monoamine 
transporter genes.10  
 
B. Structure of MATs 
The first homologue of a monoamine transporter to be crystallized was the leucine 
transporter (LeuT) from the bacterium Aquifex aeolicus.2 This transporter was crystallized 
in 2005 and has 12 transmembrane helices with a pseudo-2-fold axis in the membrane 
plane.2 This protein shares 20% identity with the eukaryotic NSSs.2 There are currently 
22 published crystal structures of LeuT with multiple drugs that are in various states of 
the transport cycle. DAT, the first of the monoamine transporters to be crystallized in 
2013, was crystallized from the fruit fly Drosophila melanogaster (i.e., dDAT).3 Several 
point mutations (V74A, V275A, V311A, L415A, and G538L) and modifications were used 
to induce the transporter to crystallize.3 Amino acid residues 1-20 as well as extracellular 
loop 2 (EL2) 164-206 were removed.3 Amino acids 602–607 were replaced by a C-
terminus green fluorescent protein (GFP–His8) tag with a thrombin cleavage site 
(LVPRGS).3 Recombinant Human Anti-Dopamine transporter antibody antigen binding 
fragment (Fab) 9D5 at a ratio of DAT:Fab 1:1.1 was also used to enhance crystallization.3 
There are 14 current crystal structures of the Drosophila dopamine transporter (dDAT) 
bound to both releasing agents and uptake inhibitors (Table 1). All structures are either 
in the outward facing state (from inhibitors) or in the partially occluded state (from 
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releasing agents). The inward facing and occluded conformations have still not been 
crystallized. The uptake inhibitors that have been crystallized are nisoxetine, reboxetine, 
RTI55, win35428, cocaine, and nortriptyline.3,15 The releasing agents are 3,4-
dichlorophenethylamine, methamphetamine, and dextroamphetamine.15 DA, the 
endogenous ligand, has also been crystallized with dDAT.15 The dDAT crystal structure 
was a leap forward in modeling the human dopamine transporter (hDAT) as it shares 
greater than 50% identity.3  
 
 




Agents Mutation Reference 
Inhibitors     












4XNX 3.00 Reboxetine V74A/L415A 
Penmatsa 
2015 
4XP5 3.30 RTI55 V74A/L415A Wang 2015 
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4XPG 3.21 Win35428 D121G/S426M Wang 2015 
4XPB 3.05 Cocaine D121G/S426M Wang 2015 
4XPF 3.27 RTI55 D121G/S426M Wang 2015 
4XP4 2.80 Cocaine V74A/L415A Wang 2015 

















4XP9 2.80 Dextroamphetamine V74A/L415A Wang 2015 
Endogenous     
4XP1 2.89 Dopamine V74A/L415A Wang 2015 
 
 
The human serotonin transporter (hSERT) was first crystallized in 2016.4 There are 
currently three different constructs of the crystallized transporter. There is the N- and C-
terminally truncated wild-type (ΔN72, ΔC13), ts3 which contains the thermostabilizing 
mutations Y110A, I291A, and T439S, and ts2 which is identical to ts3 without the Y110A 
mutation.4 Both ts2 and ts3 also have had mutations of the surface-exposed cysteines 
C554A, C580A, and C622A.4 These constructs are then fused to a C-terminus GFP and 
aProtein Data Bank ID; bX-ray. 
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then tagged with twin Strep and a decahistadine for purification.4 Two different 
recombinant antibody fragments have also been used to help crystallization, Fab 8B6 and 
15B8.4 Only Apo-state hSERT and reuptake inhibitors bound in hSERT have been 
crystallized. These inhibitors are Br-citalopram, (S)-citalopram (escitalopram), paroxetine, 
sertraline, fluvoxamine, Br-paroxetine, and levoparoxetine.4,17-19  
 
Table 2. hSERT crystal structures.4,17-19 
PDB ID Method Resolution 
(Å) 
Agents Mutation Reference 
5I6Z X-ray 4.53 Apo ts2 Coleman 2016 
5I74 X-ray 3.395 Br-Citalopram ts3 Coleman 2016 
5I73 X-ray 3.24 Escitalopram ts3 Coleman 2016 
5I75 X-ray 3.49 Escitalopram, 
Br-Citalopram 
ts3 Coleman 2016 
5I6X X-ray 3.14 Paroxetine ts3 Coleman 2016 
5I71 X-ray 3.15 Escitalopram ts3 Coleman 2016 
6AWO X-ray 3.534 Sertraline ts3 Coleman 2018 
6AWN X-ray 3.62 Paroxetine S439T Coleman 2018 
6AWQ X-ray 4.046 Sertraline ts3 Coleman 2018 
6AWP X-ray 3.8 Fluvoxamine ts3 Coleman 2018 
6W2B X-ray 4.7 Br-Paroxetine ts2 Coleman 2020 
6W2C X-ray 6.3 Levoparoxetine ts2 Coleman 2020 
11 
 
6DZW Cryo-EM 4.3 Paroxetine ts2 Coleman 2019 
6DZV Cryo-EM 4.2 Ibogaine WT Coleman 2019 
6DZY Cryo-EM 4.1 Ibogaine ts2 Coleman 2019 
6DZZ Cryo-EM 3.6 Ibogaine WT Coleman 2019 
6VRK Cryo-EM 4.1 Br-Paroxetine WT Coleman 2020 
6VRL Cryo-EM 3.8 Levoparoxetine WT Coleman 2020 
6VRH Cryo-EM 3.3 Paroxetine WT Coleman 2020 
 
 
Not only are there X-ray crystal structures but also cryo-EM structures for hSERT. 
Because of cryo-EM and the non-competitive inhibitor ibogaine, all conformations 
(outward facing, partially occluded, occluded, and inward facing) of hSERT have been 
reported.17 Also due to citalopram orthosteric and allosteric sites of hSERT are known.4 
There are currently 19 published structures of hSERT (Table 2). NET has still not been 
crystallized to date. Other unexplored crystal structures are SERT with releasing agents, 
human DAT (hDAT), DAT with its occupied allosteric site, DAT occluded, DAT inward 
facing, and any of the above transporter with a partial releaser.  
 
C. Pharmacology of MATs 
The regulation of the transporters has been associated with multiple neuropsychiatric and 
other disorders (Table 3). 1 There are several pieces of evidence that support this 
association. The first is that therapeutic agents used to treat mood disorders target DAT, 
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NET, and SERT.10 Second, monoamine transporter over expression/under expression 
have been shown to be prevalent in psychiatric and neurological disorders such as 
ADHD, depression, and Parkinson's disease.10 This has been determined both through 
binding techniques in post mortem brain samples and brain imaging techniques.10 
 
 
Table 3. Association of SLC6 family members with substrate and human disease.1  
Transporter Human Gene Substrate Disease Association 




DAT SLC6A3 Dopamine Addiction, ADHD,  
Major affective disorder, 
Parkinson’s disease,  
Tourette’s syndrome 
SERT SLC6A4 Serotonin Anxiety, Autism, Depression, 
Gastrointestinal disorders, 






D. Transporter Ligands and Drugs of Abuse 
All agents that are affiliated with the monoamine transporters work under three modes of 
action. First, the endogenous ligands are substrates for the transporters and are co-
transported with ions through the transporter into the cell.13  The second type are 
inhibitors that will bind to the transporter in its outward facing state and prevent the 
transition to an occluded state.13 The third type of agent’s, known as releasers, mode of 
action is substrate-like but they also induce a reverse function of the transporter causing 
an efflux of endogenous monoamine neurotransmitters extracellularly (Figure 3).20 Once 
the transporter is in the inward state releasing the agent intracellularly, endogenous 
ligands are then transferred in the reverse direction extracellularly.20 There is a subclass 
of these releasers that are known as partial releasers.21 They function like releasers but 






Figure 3. Representation of uptake versus releaser efflux cycle. To is the transporter 
facing outward. Ti is the transporter facing inward.21 
 
The inhibitors make up the largest variety of these agents on the market. Many drugs of 
abuse directly affect the transporters. Of this category of drugs, all act either as a releaser 
or an inhibitor. Both types of agents have the same outcome with an overall increase in 





The most widely abused and infamous releasers are amphetamine (AMPH, 4) and 
methamphetamine (5). Both these agents are Schedule II in the United States. As such, 
they have limited medical use but a high potential for abuse, with use potentially leading 
to psychological or physical dependance.22 The severe behavioral effects of these agents 
are related to the release of excess DA into the synaptic cleft of dopaminergic neurons.23 
N-Methylated AMPH, that is, methamphetamine (5), has been shown to have increased 
potency compared to AMPH.23   
 
 
Figure 4. Structures of selected releasing agent drugs of abuse.  
 
The chewing of khat leaves (Figure 5) has been practiced for hundreds of years in middle 
eastern countries to produce a stimulant effect.24 The stimulant effects are primarily due 
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to the chemical agent cathinone (6), a naturally occurring psychoactive alkaloid that is a 
beta ketone analog of amphetamine (4) as well as a potent releasing agent.24 
  
 
Figure 5. A) A field of khat plants. B) A bundle of fresh khat leaves.25 
 
The first synthetic cathinone derivative reported was methcathinone (7) in 1928,26 
although the term “methcathinone” was not coined until 1987.27 Like amphetamine (4) 
increasing in potency with N-methylation to methamphetamine (5), methcathinone (7) 
was considered in the same vein with N-methylation of cathinone (6).27 The recreational 
use of methcathinone (7) has been mostly reported in former USSR countries but gained 
popularity in the USA during the 1990s.24,28 Recently the majority of new psychoactive 




They are usually sold as "legal highs" and multiple synthetic cathinone analogs have 




The most infamous inhibitor drug of abuse is cocaine (8) which is the major active 
stimulant of the coca leaf (Erythroxylon coca).30,31 The leaf is widely used and chewed in 
South America as an anti-fatigue agent.30 While cocaine itself is a Schedule II drug with 
legitimate medical use, there is a worldwide drug abuse problem with it.31 Cocaine (8) is 
a nonselective inhibitor across all three MATs, but the main action that contributes to 
cocaine’s (8) and all inhibitor drug of abuse’s abuse potential is the inhibition of DAT 
allowing for an increase of DA concentration in the synaptic cleft of dopaminergic 
neurons.31    
 
 




Methylphenidate (9) is another well-known inhibitor drug with high potential for abuse.32 
Like cocaine, it is Schedule II.33 It differs in the fact that it has little to no activity at SERT 
and is much more selective for the other two MATs, DAT and NET.34 Synthetic cathinones 
have been found to be inhibitor drugs of abuse as well. 3,4-Methylenedioxypyrovalerone 
(MDPV, 10) was the first popularly abused synthetic cathinone found to be an inhibitor.35 
MDPV (10) is more potent than both cocaine (8) and methylphenidate (9) at DAT and was 
placed under Schedule I as of 2011. 33,36,37 -PVP (11), the des-methylenedioxy analog 
of MDPV (10), started appearing more often on the clandestine market after the ban on 
MDPV and its sale was first restricted in 2014.33,38  -PVP (11) is about equipotent to 
MDPV (10) and like both methylphenidate (9) and MDPV (10) is highly selective for DAT 
and NET.39 
 
3. Partial Releasers 
Partial releasers, a sub class of releasers, display their partial release characteristics due 
to inducing neurotransmitter efflux at a slower rate than full releasers.40 This unique 
property presents compounds with lower EMAX which is the maximum response an agent 
can produce compared to the full releaser D-amphetamine.40 Compounds 12 and 13 have 
both been identified as partial releasers.40 Compound 12 has an EC50 of 622 nM but its 
EMAX is only 61%.40 Likewise, 13 presents an EC50 of 1207 nM and an EMAX of 66%.40 The 
EMAX of both compounds is much lower when compared with the full releaser AMPH with 
an EMAX of 103%.40  
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The exact mechanism underlying the action of partial releasers remains unknown. 
However, the “partial release” by certain agents might be assay related. For example, 
some substituted AMPH analogs that behave as partial releasers in a synaptosome assay 




Figure 7. Structures of selected partial releasing agents.40 
 
The possible therapeutic applications of partial releasers are still undetermined. Partial 
releasers have been shown to display less abuse liability.41 These types of compounds 
have the potential to be developed into useful drugs due to their lower abuse potential.  
 
E. Assay Methods 
A variety of methods have been used to characterize MAT releasing agents and reuptake 
inhibitors. The information that each assay exhibits makes up the majority of what is 
known about DAT and agents that act at DAT. Here only two methods will be described 
20 
 
in detail. The first assay is the APP+ inhibition assay.42 It allows the characterization of 
both inhibitors and releasers but does not differentiate between the two.42 The second 
assay is the Ca2+ flux assay.43 This assay is a more recent development and allows for 
the differentiation between releasers and inhibitors.43 
 
1. APP+ ASSAY 
One method for examining possible emerging stimulant drugs of abuse is using an APP+ 
inhibition assay.  This assay uses human embryonic kidney (HEK) 293 cells with an 
overexpression of the transporter of interest. 4-(4-Dimethylamino)phenyl-1-
methylpyridinium (APP+, 14) is a fluorescent compound that is a substrate for the 
monoamine transporters (Figure 8).44 It is only fluorescent when transported within the 
cell.44 This is primarily due to the conformation the molecule takes intracellularly which 
increases its conjugation and lowers the excitation band gap.45 The assay proceeds by 
exposing the cells to an agent of interest followed by a mixture of the agent and APP+ 
(14).42 If a dose dependent decrease of fluorescence is observed the agent of interest is 
competitively inhibiting APP+ from interacting with the transporter.42 Through this method 
both releasing agents and inhibitors are able to be examined for functional activity but not 
differentiated. Figure 8 depicts the fluorescence of APP+ when interacting with HEK293 
cells stably expressing hDAT. Each amorphous circle is a cell and the bright white color 
is the fluorescence emitted at a wave length of 540 nm using an excitation wave length 







Figure 8. Structure of APP+ (14) and fluorescence of HEK293 cells stably expressing 
hDAT exposed to APP+. 
 
2. Ca2+ Flux Assay 
A calcium flux assay can be used to distinguish the two types of agents. In this assay 
HEK293 cells expressing the MAT transporter of interest are also transiently transfected 
with voltage gated calcium channels (Cav1.2) .43 Fura2 is a membrane permeable 
fluorescent dye that only fluoresces upon binding to intracellular calcium ions.43 The 
assay is carried out by exposing the cells to fura2 and then washing away the excess 
solution.43 The agent of interest is then perfused to the cell and fluorescence is measured 
using a fluorescence microscope.43 Upon a substrate being transported intercellularly, 
the cell becomes depolarized causing the calcium channels to open and a flux of calcium 
ions enter the cell (Figure 9).46 These ions interact with the intracellular fura2 and cause 
22 
 
fluorescence to occur.43 Inhibitors however, block the transporter thereby disallowing any 
depolarization to occur and the calcium channels stay closed.43 No fluorescence is 









Figure 9. Releasers (e.g., AMPH, 4) cause Ca2+ efflux by Ca2+ channel activation 
through cellular depolarization. Inhibitors (e.g., MDPV, 10) do not activate Ca2+ 
channels.46 
 
F. Cathinone SAR 
After the discovery of the stimulant effects of cathinone from the khat plant several other 
synthetic cathinone compounds were found to have stimulant effects.5,47 Early studies 
using rabbit synaptosomes pretreated with [3H]DA showed that cathinone (6) was a 
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releasing agent.48 Later it was found that of the two possible isomers of cathinone (6) the 
S isomer 6s was more potent than the R isomer 6r in drug discrimination studies.49 
 
 
Figure 10. Structures of the two isomers of cathinone (6). 
 
The first synthetic cathinone, methcathinone (7) was found to be even more potent than 
cathinone.27 Many other synthetic cathinones have been examined for activity with 
modifications at the phenyl ring (R1), alpha carbon (R2), and the amine (R3) (Figure 11).5 
 
 






1. Aryl Substitution 
Few ring substitutions have been examined for cathinone (6). Of the agents tested 15-
18, all failed to produce locomotor stimulation in mice.50 Compound 19 failed to generalize 
in rats trained to discriminate cathinone (6) from saline vehicle while 20 showed partial 
generalization.51 
   
 
 
Figure 12. Structure of cathinone analogs with selected aryl substitutions.  
 
Compound 21 produced partial generalization for amphetamine (4) trained rats but fully 
substituted in rats trained with the empathogen N-methyl-1-(3,4-methylenedioxyphenyl)-
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2-aminopropane (MDMA).52 Several ring substitutions have been examined for 
methcathinone (7) as well.30 
 
 
Figure 13. Structure of methcathinone analogs with selected aryl substitutions. 
 
Compound 22 stimulated locomotor activity in rats at 10 mg/kg, double the dosage of 
methcathinone (7), 5 mg/kg.53 Analogs 23 and 24 were found to not produce any 
hyperactivity at all doses tested.53,54 The cathinone analog of MDMA, 25, generalized for 
both amphetamine (4) trained rats and MDMA trained rats.52 It was, however, 6-fold less 
potent than methcathinone (7) in the amphetamine (4) discrimination assay. 52 
Mephedrone (26) has been shown to be a DA releasing agent with a similar EC50 (1.19 
M) but with less percent of maximum release (68%) when compared to methcathinone 
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(7) (3.57 M, 83.3%) in a [3H]DA release assay using HEK-293 cells expressing hDAT.55 
Compound 27 on the other hand, exhibited opposite behavior to mephedrone (26) with a 
larger EC50 (17.8 M) but a higher percent maximum release (98%).55  
 
2. -Methyl Modification 
-Desmethylcathinone (28) was not active and failed to substitute at up to 10 times the 
ED50 dose of cathinone (6) both in rats trained to discriminate amphetamine (4) and rats 
trained to discriminate cathinone (6) from saline vehicle.49,51 When tested as a releasing 
agent with [3H]DA in rat synaptosomes, 28 was found to be about one-fourth to one-third 
as potent as cathinone (6).56,57 
 
 
Figure 14. Structure of cathinone analogs with selected -methyl modifications.  
 
Conformationally constraining the -methyl group into a ring 29 also failed to substitute 
at 10 times the ED50 dose of cathinone in discrimination studies.56 Analog 29 was about 




3. Amine Modification 
Homologation at the amine beyond N-methyl to N-ethyl (i.e., 30) and N-propyl (i.e., 31) 
lowered stimulant potency in drug discrimination studies.52 
 
Figure 15. Structure of cathinone analogs with selected amine modifications. 
 
Increased branching of the amine substituent with an isopropyl group (i.e., 32) or tert-
butyl (i.e., 33) resulted in diminished potency in locomotor activity assays compared to 
methcathinone (7).53 It was also found N,N-dimethylcathinone (34) was about half as 
potent as methcathinone and it was later discovered that in human subjects about 45% 





4. Inhibitor Cathinone Deconstruction 
MDPV (10) being the first DAT inhibitor cathinone found on the clandestine market 
promoted research on the deconstruction of this cathinone to examine the structural 
features that contribute to its DAT inhibitory effects.59 All MDPV (10) deconstruction 
analogs tested behaved as DAT reuptake inhibitors although with varying degrees of 




Figure 16. Deconstruction of MDPV (10). IC50 values represent potency to block 
reuptake of DA. Each arrow represents one structural modification.39 
 
The loss of the methylenedioxy ring to form -PVP (11) showed little change in inhibitory 
activity compared to the parent compound which provides evidence that the ring is not 
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necessary.39 All other deconstructions (i.e., 35-40) were much less potent than MDPV 
(10).39 Removal of the carbonyl oxygen (i.e., 35) showed around a 10-fold loss in 
potency.39 This is unique for inhibitor drugs of abuse as a large potency drop is not seen 
in the releasing agents (i.e., methcathinone (7) to methamphetamine (5)).60 The other 
analogs reduced potencies demonstrate the two most important features for high DAT 
inhibition activity. The first is bulk of the pyrrolidine ring. Alteration of this ring to a simpler 
tertiary (i.e., 36), secondary (i.e., 37), or primary (i.e., 38) amine greatly reduces DAT 
inhibition potency in a stepwise manner with the primary amine 38 being the weakest 
inhibitor compound.39 The second most important feature is the extended -alkyl side 
chain. Truncation of this chain alone (i.e., 39) reduces potency by 25-fold.39 Modification 
to both the pyrrolidine ring and the alkyl side chain (i.e., 40) showed the second largest 
drop in potency with an IC50 of 22,300 nM.39       
 
5. Inhibitor Cathinone Elaboration 
-PVP (11), the des-methylenedioxy analog of MDPV (10) and roughly equipotent in DAT 
inhibition, was used as a scaffold in a series of elaborations to explore the SAR of the 
alkyl side chain and the pyrrolidine ring size of these inhibitor cathinones (Table 4).61 It 
was found that reducing the length of the side chain (i.e., 41-43) decreased potency in a 
stepwise manner.61 Branching from n-propyl (i.e., 11) to iso-propyl (i.e., 44) reduced 
potency as well.61 Elongation from n-propyl (i.e., 11) to n-butyl (i.e., 45) increased 
potency.61 Adding a cyclopentyl ring (i.e., 46) was equipotent to the parent compound 
while elaboration to a cyclohexyl ring (i.e., 47) increased potency and was the most potent 
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compound of the series.61 Modifying the pyrrolidine ring to a piperidine ring decreased 
potency for both compounds tested (i.e., 48, 49).61 As seen with other cathinones 
conformationally constraining the alkyl side chain back to the aryl ring (i.e., 50) showed a 
large drop in potency.61 
 
Table 4. Inhibition of [3H]dopamine uptake in synaptosome assay by elaborated 
analogs of  -PVP (11).61 
 
Compound -R IC50, nM 
41 -H 3250.0 
42 -CH3 196.7 
43 -CH2CH3  63.3 
11 -CH2CH2CH3  17.5 
44 -CH(CH3)2  92.3 
45 -CH2(CH2)2CH3  11.6 
46 -C5H9  17.1 
47 -C6H11  8.3 
48 -CH3  2490.0 
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49 -CH2CH2CH3  128.0 
50  12900.0 
 
 
To summarize what is currently known about the SAR of cathinones: by adding bulk to 
the alpha carbon (R2) or changing the primary amine to a bulky secondary or tertiary 
amine (R3) caused the action of these agents to change from a releaser to an inhibitor 
(Figure 11).5 Also, selectivity for the different transporters can be affected through 
molecular modification. Cathinone (6) is a releaser for all of the monoamine transporters.5 
Adding bulk onto the alpha carbon (R2) shifts selectivity more towards DAT and NET.5 In 
contrast, adding a methylenedioxy ring or a trifluoromethyl substituent on the aromatic 
ring (R1) shifts the selectivity of the compounds more towards SERT than DAT or NET.5,12 
All these different alterations to the backbone of the molecules do interplay with each 
other. MDPV (10), the potent DAT inhibitor, that has the methylenedioxy ring on the 
aromatic ring (R1) has no activity towards SERT due to its large alpha alkyl side chain 
(R2) and its tertiary amine (R3) from the pyrrolidine ring.5 Cathinone (6) has a chiral center 
as well () (Figure 11). The stereochemistry does affect the overall potency of cathinones. 
Both R and S isomers have been shown to be active with S being shown to be the eutomer 






G. Methylphenidate SAR 
Methylphenidate (9), a well-studied and widely prescribed drug on the market, is primarily 
used for the treatment of ADHD.62 It was first synthesized in 1944 but was not discovered 
to have stimulant activity until 10 years later.63,64 The first clinical use of methylphenidate 
(9) was as an analeptic from barbiturate-induced coma.41 The original patent of 
methylphenidate (9) was for its preparation by CIBA pharmaceuticals in 1950 then later 
patented for method of use in 1954 as a treatment of psychiatric disorders.65 It has a bulky 
secondary amine and an extended alpha alkyl side chain that connects back to the amine 
to make up a piperdine ring. These features contribute to the compound’s character as 
an inhibitor that is selective towards DAT and NET as well as showing little to no activity 
at SERT.66 There are four stereoisomers of methylphenidate (9) (Figure 17) and there is 
a high eudysmic ratio between the RR and SS enantiomers.67 Dexmethylphenidate (d-
threo-methylphenidate), the RR enantiomer of methylphenidate (9), is the eutomer of the 
four isomers.6,67,68  
 
 




A crystal structure of the inactive conformation of l-threo-methylphenidate (9) has been 
solved (Figure 18) with the monoclinic crystal in the P21 space group.69 In addition, with 
the use of this crystal and the MM2-87 program a global minimum of the active d-threo-
methylphenidate (dt9) was also obtained.69 In the active d-threo-methylphenidate (dt9) 
conformation it can be observed that the protonated piperidine nitrogen can form an 
interaction with the carbonyl oxygen at a distance of 3.32 Å.69 
 
 
Figure 18. (A) Global minimum of d-threo-methylphenidate (dt9) (B) Solved crystal 
structure of l-threo-methylphenidate (lt9).69 
 
The chemical space of methylphenidate has been explored exhaustively (Figure 19).6 A 








Figure 19. SAR features that have been quantitatively explored for dt9.70 
 
Substituents have been added and tested on the aromatic ring, the ester has been 
modified, and the piperdine ring has been added to as well as ring size altered (Figure 
19).6 All further discussion of methylphenidate analogs will be concerned with the racemic 
mixture of threo-methylphenidate (t9).  
 
1. Aryl Substitution 
A series of aryl substituted analogs of methylphenidate (9) were examined for [3H]WIN 
35,428 binding and [3H]DA uptake.6,71 All 2-substituted compounds had weaker binding 
and were less potent than t9 at uptake inhibition.71 In the 3-position all halogens and 
hydrophobic groups evaluated were more potent than t9 while all hydrophilic electron 
donating groups (EDG) were less potent.71 The 4-position reveals a similar trend as the 
3-position substituents having halogens and hydrophobic groups showing more potency 
than t9 but with less increases in potency.71 A hydrophilic EDG, 4-NH3•HCl analog (i.e., 
73), was twice as potent as t9 indicating that hydrophobicity and electronic character may 
not be responsible for potency at the 4-position but instead volume of the substituent.71 
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Table 5. DAT binding affinity (IC50, nM) and uptake inhibition potency (IC50, nM) of aryl 
substituted methylphenidate (9) analogs 51-79.6,71 
 
 
Compound -R Bindinga (IC50, nM)  Uptakeb (IC50, nM) 
t9 -H 83 224 
51 2-F 1420 2900 
52 3-F 41 160 
53 4-F 35 142 
54 4-CF3  615 - 
55 2-Cl  1950 2660 
56 3-Cl  5 23 
57 4-Cl  21 74 
58 3,4-diCl  5 7 
59 3,5-diCl  67 - 
60 2-Br  1870 3410 
61 3-Br  4 13 
62 4-Br  7 26 
63 4-I  14 65 
64 2-OH  23100 35800 
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65 3-OH  321 790 
66 4-OH  98 340 
67 2-MeO  101000 81000 
68 3-MeO  288 635 
69 4-MeO  83 293 
70 3,4-diMeO  810 1760 
71 4-NO2  494 1610 
72 3-NH2•HCl  265 578 
73 4-NH2•HCl  35 115 
74 3-Me  21 100 
75 4-Me  33 126 
76 3,5-diMe  4690 - 
77 4-Et  737 - 
78 3,4-benzo  11 53 
79 4-t-Bu  13500 9350 
                a[3H]WIN 35,428 radioligand. b[3H]DA substrate. 
 
Also, there was an exception of 4-NO2 and 4-t-Bu analogs (i.e., 71 and 79) being less 
potent than compound t9 suggesting that there is a limit to the size of the substituents at 
the 4 position.71 A hydrophobic electron withdrawing group (EWG), 4-CF3 analog 54, with 
a similar size to 4-Me and 4-Cl, was less potent than compound t9.6 This substituent has 
a higher polarizability or negative hyperconjugation that might explain the difference seen 
in 4-CF3 from the other substituents at the 4-position. For disubstituted compounds, 3,4 
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and 3,5 were the only positions tested.6,71 All disubstituted compounds evaluated saw an 
increase in potency from EWGs and a decrease in potency from EDGs compared to 
(t9).6,71    
 
2. Amine Substitution 
Alkylation of the piperidine amine group has been examined.6 Alkylation such as methyl 
80, allyl 81, and propynyl 82 reduced affinity.6 Addition of benzyl type groups had mixed 
results (i.e., 83-94). The only substitutions that had better binding than compound t9 were 
benzyl 83 and p-Cl-benzyl 92. p-MeO-Benzyl (94) was similar in potency to t9 whereas 












Table 6. [3H]WIN 35,428 binding affinities (IC50, nM)  of methylphenidate (9) analogs 
with amine substituents.6 
 
Compound -R  (IC50, nM) 
t9 -H 83 
80 -CH3 499 
81 -CH2CHCH2 597 
82 -CH2CCH 821 
83 -Bn 53 
84 -MeBn 678 
85 -EtBn 267 
86 -PrBn 205 
87 -BuBn 1570 
88 -PeBn 656 
89 -Bn-p-NCS 422 
90 -Bn-m-Cl 106 
91 -Bn-o-Cl 243 
92 -Bn-p-Cl 31 
93 -Bn-p-NO2 113 
94 -Bn-p-MeO 79 
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95 -2-Pyridyl 369 
96 -3-Pyridyl 173 
97 -4-Pyridyl 128 
98 -2-furyl 536 
99 -3-furyl 459 
100 -2-thienyl 224 
101 -3-thienyl 143 
 
 
2-, 3-, and 4-Pyridyl groups were also examined (i.e., 95-97) of which all were weaker in 
comparison to t9.6 Likewise, 2- and 3-furyl 98, 99 and thienyl 100, 101 analogs were 
tested as well with weaker affinities.6 
 
3. Ester Modifications 
Several substituents have been examined in place of the ester group on methylphenidate 
(t9) (Table 7).6,72 All modifications tested showed lower affinity when compared to the 
parent compound.6,72 The methyl Et2O 103 was the only compound tested with a similar 
















4. Ring Modifications 
Modification of the piperidine ring has also been explored from a 5-membered ring all the 
way up to an 8-membered ring as well as a change to a morpholine ring (Table 8).73 The 
piperidine ring of t9 was the most efficacious followed by the 7-membered ring analog 
which had 2-fold lower affinity and 3-fold lower potency.73 While the morpholine analog 
contains a 6-membered ring like the parent compound t9, it had the lowest affinity and 
Compound -R (IC50, nM) 
t9 -CO2CH3 83 
102 -CH2OH 448 
103 -CH2OCH3 97 
104 -CO2Bn 1020 
105 -CH2O(CO)CH3 690 
106 -CO2NH2 1730 
107 -H 6360 
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activity of all the analogs tested.73 It can be concluded then that the oxygen atom of the 
morpholine ring is not well tolerated by DAT.73   
 
Table 8. DAT binding affinity (IC50, nM) and uptake inhibition potency (IC50, nM) of 
piperidine ring modified methylphenidate (t9) analogs 108-111.73 
 
Compound Ring Size Bindinga (IC50, nM) Uptakeb (IC50, nM) 
108 5  355 885 
t9 6  83 224 
109 6-morpholine 1250 9930 
110 7 197 701 
111 8 623 1590 




Of all the modifications explored for methylphenidate, only EWG substitutions at the meta 
or para position that are within the plane of the phenyl ring correlate with increased DAT 
affinity and activity.6 Large substituents in the ortho position, substituents above and 
below the plane of the aryl ring, substitutions on the piperdinyl nitrogen atom, and 
decreasing polarity near the carbonyl moiety all correlated with decreased DAT activity.6  
 
H. New Methylphenidate/Cathinone Hybrids 
Portoghese proposed that if two different series of compounds with the same change in 
substituents have parallel changes in binding affinity then they likely bind in a similar 
manner.74 With the large number of synthetic cathinones coming onto the grey market as 
drugs of abuse, is it possible to predict new cathinone activity by using the SAR of the 
well-studied methylphenidate compounds? Our lab developed a hybrid 






Figure 20. Cathinone (6)/methylphenidate (t9) hybrid compound 112.7  
 
The hybrid 112 has the ketone of cathinones as well as the piperidine ring of 
methylphenidate. The hybrid was evaluated for reuptake inhibition using the APP+ assay 
as well as for DAT releaser or inhibitor properties using the Ca2+ assay (Figure 21).7 It 











Figure 21. Ca2+ efflux assay of selected hybrid compound 112 showing DAT inhibitor 
properties.7 
 
It was also determined that 112 was not a releaser and shared the inhibitor properties of 
methylphenidate (Figure 21).7 Using a series of 8 hybrid compounds (i.e., 112-119) it was 
shown that parallel activity existed in substituent alterations at the aromatic ring of the 
hybrid compound’s potencies compared to the corresponding methylphenidate analog’s 







Table 9. DAT uptake inhibition potency (IC50, nM) of aryl ring modified hybrid (i.e., 112) 
compounds and DAT binding affinity (IC50, nM) of corresponding aryl-ring modified 
methylphenidate (9) analogs.7 
 
aAPP+ substrate. b[3H]WIN 35,428 radioligand. 
 
A plot comparing the hybrid series inhibition pIC50’s to the affinity pIC50’s of the 




-R1 -R2 Uptake (IC50, nM) t9 Analogs Binding 
(IC50, nM) 
112 -H  -H 1080 9 83    
113 -CH3  -H 380 75 33  
114 -C2H5  -H 6900 77 737  
115 -Cl  -H 520 57 21  
116 -Br  -H 590 62 7  
117 -OCH3  -H 2340 69 83 
118 -CF3  -H 14300 54 615 






Figure 22. Correlation (r = 0.91) of APP+ uptake assay data of hybrid (i.e., 112) 












III. Specific Aims and Rationale 
A. Project 1. 
Aim 1. Construct a new hDAT homology model 
DAT is an important transporter that is implicated in a multitude of neuropsychiatric 
disorders. The function and crystal structures of MATs has only been established in the 
past 20 years. Even with the advancements in structural biology, hDAT has still not been 
crystallized. In order to better understand this important transporter several different 
methods will be used to approach the exploration of hDAT from different perspectives. 
One strategy is to understand how novel agents (see below) bind at hDAT, and the 
second is to examine several known DAT reuptake inhibitors at dDAT mutants 
transitioning from dDAT to hDAT. Both of these projects will utilize a new DAT homology 
model that we propose to construct. Hypothesis: Using the most recent MAT 
homologues with high identity compared to hDAT it should be possible to develop a more 
accurate model than what has been used in the past. Using this new homology model, 









Aim 2. Elucidate factors determining the potency of 3,4-disubstituted 
cathinone/methylphenidate hybrids 
a. Synthesis 
Synthetic cathinones are a newer drug abuse problem that is causing alarm worldwide. 
With greater than 150 synthetic cathinones already identified and even more emerging 
every year there is great interest in better understanding the SAR of these compounds. 
MDPV (10) was the first discovered abused reuptake inhibitor synthetic cathinone. What 
is known about the SAR of the DAT reuptake inhibitor cathinones mainly involves the 
nature of the bulky amine and extended -alkyl side chain. Little is known about 
substituents around the aryl ring. Methylphenidate (9) is a well-known DAT reuptake 
inhibitor with extensive SAR established. Our lab developed a cathinone/methylphenidate 
hybrid that exhibits DAT reuptake inhibition. A series of these hybrid compounds was 
developed and used to explore DAT SAR in comparison to corresponding 
methylphenidate analogs. The most potent compound of the hybrid series (i.e., 112) was 
shown to be even more potent than methylphenidate: the 3,4-dichlorobenzoylpiperdine 
analog 119. What is it about this compound that makes it so potent? To exam this 
phenomenon we designed two additional hybrid compounds that will help elucidate why 





Figure 23. Structures of hybrid compound 112,74 potent hybrid compound 119,74 and 
two proposed new compounds 120 and 121.  
 
The two new compounds take into account steric, electrostatic, hydrogen bonding, and 
halogen bonding effects (Table 10). The first compound is 3,4-dimethylbenzoylpiperdine 
120. The two methyl groups are about the same size as the chloro groups of 119 but with 
opposite electronic character. Chloro groups are weakly electron withdrawing while 
methyl groups are electron donating. Hypothesis: If electronic character is driving the 
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increase in activity the 3,4-dimethylbenzoylpiperdine 120 should be less potent than the 
dichloro 119 compound. If electronic character is not important for activity, then the 
dimethyl compound should have similar activity. The second compound is the 2-
naphthoylpiperdine 121. This compound has the additional conjugated ring to the phenyl 
ring at the 3,4 positions.  
 
Table 10. Lipophilic (), electronic (), steric (Vol), hydrogen bond (HB) acceptor, and 
halogen bond formation properties of compounds 119-121. 
Parameter 119 120 121 
 1.46a 1.03b 1.32a 
 0.60c -0.24c 0.08a 
Vol (Å3)d 90.9 88.2 100.0 
HB Acceptor Yes No Yes 
Halogen Bond Yes No No 
a Values as reported by Hansch et al.75 b Values as reported by Fujita et al.76 c Values as 
reported by Jaffé.77 d Volume measured using SybylX 2.1.1. 
 
It is slightly larger in size compared to the dichloro substituents of 119 and has similar 
electron withdrawing character. It is usually seen as a bioisotere for 3,4-dichlorophenyl 
substituents. What is different about 121 is that it does not have the ability to form halogen 
bonds. This halogen bond activity is due to the anisotropic nature of halogen substituents. 
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The halogen forms a -hole that has positive electronic nature and can be viewed as a 
Lewis acid (Figure 24). This -hole can then interact with a Lewis base such as a lone 
pair from a hetero atom. Hypothesis: If 121 is less potent than the dichloro compound 
119 then the dichloro compound might have increased potency through hydrogen or 
halogen bond formation. If the naphthoyl compound 121 has similar potency to the 
dichloro compound then halogen bond formation is less likely and only the size (i.e., 
volume) of the substituents, hydrogen bonding, or possibly electronic  character is 
important for activity. The extended aromatic ring of compound 121 has a delocalized  
cloud above and below the face of the ring (Figure 24). This  cloud has negative 
electronic character and can participate in interactions with positively charged species 
such as hydrogen bond donors.78 This can be viewed in the same way as edge-to-face 






















Figure 24. Representation of positive and negative electrostatic interactions involving a 
halogen bonds (above) and aromatic rings (below). 
 
b. Biological Studies  
After the synthesis of each target compound (i.e., 120, 121) the APP+ assay will be used 
to evaluate their potencies. HEK Flp-In T-REx 293 cells stably expressing hDAT will be 
cultured and plated in a 96-well plate. Using an imaging solution, selected concentrations 
of the target agents will be constantly perfused followed by a mixture of the target agent 
and APP+. The entire experiment will be observed and recorded using fluroescence 
microscopy. Data obtained through the recording will then be analyzed and inhibtion IC50 
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After developing a hDAT homology model all three compounds will be docked and scored 
using Hydrophilic INTeraction (HINT) analysis. On a molecular level, the specific 
interactions with the amino acids within hDAT and the compounds will be examined. The 
particular substituent properties important for increased or decreased hDAT reuptake 
inhibition can then be possibly elucidated. The modeling data will then be compared to 
the biological data and new insights on cathinone reuptake inhibitor SAR will be 
established. 
 
B. Project 2. 
Aim. Evaluate binding modes of selected cathinones at DAT mutant transporters 
utilizing 3D molecular modeling 
Another approach to better understand DAT is mutagenesis. dDAT might be thought of 
as a natural mutant to hDAT that might display unique SAR with cathinone reuptake 
inhibitors. While both dDAT and hDAT transport the endogenous ligand DA with similar 
potencies, the potent hDAT cathinone reuptake inhibitor MDPV (10) is essentially inactive 
at dDAT (DeFelice, unpublished data). Evidently, structural differences between dDAT 
and hDAT must account for this difference. In a collaboration with Dr. Eltit’s lab, using 
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constructed four point mutations transitioning dDAT to hDAT, three synthetic cathinones 
known to be effective hDAT reuptake inhibitors will be examined at the dDAT mutant 




Figure 25. Structures of agents to be examined at dDAT mutant transporters: MDPV 
(10), -PVP (11), and MDPPP (39). 
 
Compounds 11 and 39 might be viewed as deconstructed analogs of MDPV (10). 
Compound 11 lacks the methylenedioxy ring of 10 whereas 39 possesses a shorter side 
chain. Evaluation of these compounds will assist in determining which of these two 
structural features (i.e., the methylenedioxy ring or the extended side chain) account for 
the difference in action of MDPV (10) at dDAT versus hDAT.  
Hypothesis: As the structure of dDAT transitions to hDAT favorable molecular 
interactions between ligand and protein should improve. 
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Using the previous (see Project 1) generated hDAT homology model and in addition the 
crystal structure of dDAT and a mutant model with the four mutations, docking studies 
and HINT analysis on all three agents within the models will be performed.  
 
Overall, this two-pronged approach, which can be summarized by Figure 26, will help 
















IV. Results and Discussion 
A. Project 1. 
Aim 1. Construct a new hDAT homology model 
There is no crystal structure of hDAT, thus, a homology model of hDAT was constructed 
using MODELLER 9.24. This software package makes use of a crystal structure template 
and the amino acid sequence of the protein of interest. For this particular hDAT homology 
model three separate crystal structure templates were used. The reason for multiple 
templates is based on three criteria: the highest sequence identity, the largest query 
coverage, and a crystal structure with a similar test ligand. The highest sequence identity 
allows for the most similar structure to be formed during the model build. The largest 
query coverage ensures places where there could be gaps or high amounts of ambiguity 
for model generation are minimized. Using a crystal structure that has a similar test ligand 
can help ensure that in docking studies proper interactions will take place between an 
agent of interest and the amino acids within the binding pocket. PDB ID: 4XPB, a dDAT 
crystal structure, was used due to having the highest sequence identity with hDAT at 
55.35%. This is a large improvement from previous models developed from the ortholog 
LeuT having only a 24% identity to hDAT.79 Also, homology model generation usually 
needs at least 30% identity to produce an adequate model otherwise there can be 
significant alignment errors and main chain positions can be greatly altered.80 PDB ID: 
6VRH, an hSERT crystal structure, was used due to having a 92% query coverage.81 
Having such a large query coverage crystal structure template that is in the SLC6 family 
with hDAT helps ensure that the portions of the protein that are missing from the dDAT 
crystal structure can still be sufficiently modeled. Lastly, PDB ID: 4XPT was used because 
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its co-crystallized ligand was 3,4-dichlorophenethylamine that has chloro substituents on 
the phenyl ring that correspond to the ones found in compound 119. Utilizing this crystal 
structure that has amino acids within the binding pocket possibly interacting with the two 
chloro groups in the same manner as the chloro groups from compound 119, should have 
considerable benefits when docking compounds 119, 120, and 121. The target hDAT 
sequence was obtained from NCBI accession BAA22511.1. Using this target sequence 
and the three templates, MODELLER aligned the sequences and generated 100 hDAT 
models. The models were evaluated through GA341 and DOPE scoring. The best scoring 
model was then uploaded into SybylX 2.1.1, hydrogen atoms were added, and the 
structure was minimized using the Tripos Force Field with Gasteiger-Hückel charges. The 
finalized hDAT homology model (Figure 27) was then compared to the crystal structure 
of dDAT using the biopolymer suite within SybylX 2.1.1. The calculated root mean 
squared deviation (RMSD) of all atoms was 2.16 Å. An RMSD < 3 Å for the C atoms of 
the backbone of a template and predicted protein is considered a success.82 With all 



















Figure 27. Generated hDAT homology model (cartoon) with labeled transmembrane 
(TM) helices. 
 
The generated hDAT homology model was then used to dock methylphenidate (dt9) for 
initial homology model docking studies. Methylphenidate (dt9) was first sketched using 
SybylX 2.1.1. The sketched molecule was then energy minimized using the Tripos Force 
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Field with Gasteiger-Hückel charges. Using GOLD2020, methylphenidate (dt9) was then 
used as a test ligand and cocaine (8) was used as a reference ligand in the hDAT 
homology model. Methylphenidate (dt9) was docked 100 times and scored with 
ChemPLP and GOLD. The best GOLD scoring methylphenidate (dt9) pose formed a salt 
bridge interaction with an aspartate residue (D79) (Figure 28). When compared to the 
pose of the dDAT crystallized ligand cocaine (8), both phenyl rings as well as the methyl 
ester groups had significant overlap for each compound. While the tropane ring of cocaine 
(8) and the piperidine ring of methylphenidate (dt9) differ in structure the nitrogen atom 











Figure 28. hDAT homology model (cartoon, green) with possible binding pose of 
methylphenidate (dt9, sticks, white) forming salt bridge (dotted line, yellow) with D79.  
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All 100 poses generated in GOLD2020 were then subjected to HINT analysis. Using 
SybylX 2.1.1 scripting programming language (SPL) each methylphenidate (dt9) pose 
was merged with the hDAT homology model. Each formed complex was then minimized 
using the Tripos Force Field with Gasteiger-Hückel charges. Using Sybyl 8.1, each 
complex had the test ligand removed and HINT analysis was performed. For the initial 
partitioning phase, the dictionary method was used for the protein and the calculation 
method was used for the ligand.83,84 All other parameters were set to their default values. 
The highest HINT score was 868 (Table 11). The pose of the molecule for this high HINT 
score also mimicked cocaine with the phenyl ring and methyl ester group overlapping the 
same groups of cocaine. The highest contribution to the overall scores was from the 
hydrogen bond (HB) formation with the piperidine amine and D79 (3.1 Å). HINT does not 
consider salt bridges but a salt bridge can be viewed as a kind of HB.   
 
Table 11. Total HINT score of dt9 solutions with top scores for each type of molecular 
interaction. 




Total HINT Score 868 -104 
Hydrogen Bond 646  
Acid/Base 612  
Hydrophobic 789  




Aim 2. Elucidate factors determining the potency of 3,4-disubstituted 
cathinone/methylphenidate hybrids 
a. Synthesis 
The synthesis of the target hybrid compounds (119-121) followed the same basic 
procedure (Scheme 1). Small differences occurred between the generation of each 
compound due to availability of chemicals and attempts to improve yields. 
 
Scheme 1.a General procedure for target compound synthesis. 
 
aReagents and conditions: a. (Boc)2O, Et3N, MeOH, rt, 1 h; b. N,O-dimethylhydroxylamine 
hydrochloride, BOP, Et3N, DCM, rt, 16 h; c. 2.5 M n-BuLi in hexanes, anhydrous Et2O, -
78 °C (but, see text), 3 h; d. anhydrous Et2O, -29 °C, 24 h. 
 
The synthesis of compound 119 had been previously accomplished in our laboratory and 
proceeded through what is known as a Weinreb ketone synthesis.7 The exact procedure 
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was followed for the synthesis of compound 119 with the exception of the starting material 
being pipecolic acid (122) and not N-Boc-pipecolic acid (123). For the synthesis of the 
Boc-protected intermediate, pipecolic acid (122) was reacted with (Boc)2O in methanol 
with Et3N used as a base at room temperature for 1 hour (Scheme 2). This reaction 
proceeded by generation of CO2 gas as a side product. Several reaction iterations were 
used to produce this intermediate, but this particular setup had the most optimized yields 
of all conditions tested at 95%.  
 
Scheme 2.a Synthesis of intermediate 123. 
 
aReagents and conditions: (Boc)2O, Et3N, MeOH, rt, 1 h. 
 
Following the synthesis of intermediate 123, the next step was to generate the Weinreb 
amide 124. This reaction borrows from peptide chemistry and reacts the carboxylic acid 
of compound 123 with the amine of N,O-dimethylhydroxylamine hydrochloride in DCM 
using the peptide coupling agent (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium 
hexafluorophosphate (BOP) and Et3N as a base at room temperature for 16 hours 
(Scheme 3). BOP produces the carcinogenic side product hexamethylphosphoramide 
(HMPA) during the amide coupling reaction. In future reactions of this nature, it is 
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recommended that benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate 
(PyBOP) be used as the coupling agent instead of BOP as HMPA is not formed in the 
process and the reaction produces the same yields under the same conditions as BOP.85 
The synthesis of intermediate 124 was also repeated several times and the most 
optimized setup produced a yield of 85%. The product (i.e., 124) is in most cases reported 
as a clear oil. A clear oil was obtained as the final product in this reaction but after several 
days it solidified into a white solid with a melting point of 64-66 °C. A method that was 
found to enhance the solidification process was to expose the oil to a dry ice/acetone 
cooling bath. Upon exposure to the -78 °C temperature cooling bath the oil would solidify 
and upon returning to room temperature remained in solid form. 
 
Scheme 3.a Synthesis of intermediate 124. 
 
aReagents and conditions: N,O-dimethylhydroxylamine hydrochloride, BOP, Et3N, DCM, 
rt, 16 h. 
 
An organolithium intermediate (i.e., 128) was then needed for the second portion of the 
Weinreb ketone synthesis. The intermediate was synthesized using a lithium halogen 
exchange reaction (Scheme 4). 3,4-Dichlorobromobenzene (125) was used as the 
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starting material as the bromo substituent was the halogen in the lithium halogen 
exchange. Due to the extreme reactivity of organolithium compounds and their sensitivity 
to air and moisture the reaction flask was prepped by oven drying and then using three 
cycles of gas evacuation by vacuum and back filling with dry N2 gas. Anhydrous Et2O was 
added to the flask by syringe followed by the syringe addition of compound 125. Also due 
to the sensitivity of organolithium reactions the reaction mixture was cooled to -78 °C 
using a dry ice/acetone cooling bath. n-Butyllithium (2.5 M) in hexanes was added via 
syringe in a dropwise manner over 15 minutes. This slow addition was to ensure the 
reaction did not exceed a safe rate. This reaction was allowed to run over a 3-hour period, 
although lithium halogen exchange should occur rapidly. Because organolithium products 
are difficult to characterize, intermediate 128 was generated in situ and used directly in 
the following reaction for the intermediate 131. 
 
Scheme 4.a Synthesis of intermediate 128. 
 
aReagents and conditions: 2.5 M n-BuLi in hexanes, anhydrous Et2O, -78 °C, 3 h. 
 
For the synthesis of compound 131 (the N-Boc protected target compound), 
intermediates 124 and 128 were reacted with each other in Et2O (Scheme 5). Compound 
66 
 
124 was placed in an oven-dried flask after which was evacuated by vacuum and back 
filled with N2 gas three times. Afterwards, anhydrous Et2O was added via syringe and the 
reaction mixture was cooled to -29 °C using a dry ice/o-xylene cooling bath. Once the 
reaction mixture was cooled, intermediate 128 was added via syringe in a dropwise 
manner over a 15-minute period. This slow addition time was taken to add the 
organolithium intermediate in order to avoid rapid exotherms. This reaction was allowed 
to run overnight as the Weinreb ketone reaction intermediate formed is somewhat stable. 
A reverse quenching method was employed to reduce any side product formation by 
slowly adding portions of the reaction mixture to a cold 1 M KH2PO4 solution.  
 
Scheme 5.a Synthesis of intermediate compound 131. 
 
aReagents and conditions: anhydrous Et2O, -29 °C, 24 h, 1 M KH2PO4 reverse quench. 
 
In order to generate the final target compound 119, intermediate 131 was deprotected 
and the freebase of 119 was converted to an HCl salt (Scheme 6). Deprotection and salt 
formation was accomplished in one pot by first dissolving 131 in anhydrous methanol and 
cooling the solution with an ice bath. Then, methanolic HCl was added in a dropwise 
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manner to the reaction mixture until the pH of the solution was near 1. The reaction 
mixture was allowed to stir overnight. Upon removal of solvent, washing with acetone, 
and recrystallizing using anhydrous methanol, pure target product 119 was collected with 
a melting point of 272-273 °C. This melting point corresponds to what was previously 
recorded at 273-275 °C.7 For full characterization of the target compound 119 nuclear 
magnetic resonance (NMR) spectrometry, high resolution mass spectrometry (HRMS), 
and C, H, N analysis were utilized and each analysis method confirmed successful 
synthesis and purity (Figure 29). C, H, N analysis had not previously been reported for 
compound 119.  
 
Figure 29. 1H NMR spectrum of compound 119. 
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Scheme 6.a Synthesis of target compound 119. 
 
aReagents and conditions: methanolic HCl, anhydrous methanol, 0 °C, 24 h. 
 
After the success of the first target compound (i.e., 119), synthesis of compound 120 was 
attempted. Four attempts were made to finally generate compound 120. The first attempt 
proved to be successful albeit having immensely low yields. The amount of compound 
120 obtained was just enough for characterization but not enough for future biological 
assay studies. The second attempt made use of a newer batch of the starting material 4-
bromo-o-xylene (126) in an effort to increase yields. This was in case the starting material 
had decomposed or been compromised. The second attempt yielded a higher total 
amount of a white crystalline solid than the first. The thin layer chromatography (TLC) for 
this second compound produced the same retention factor (Rf) value as the first attempt. 
Even the CombiFlash Companion/TS readout produced a similar chromatogram as the 
first attempt. Unfortunately, when it came to the melting point it was close to 100 °C less 
than for the characterized first compound (i.e., 120). Also, 1H NMR characterization 
showed that compound 120 was not present in the test sample. Attempt two was a failure 
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(Scheme 7). Further characterization was not carried out and another set of reactions 
was set up for the third attempt.  
 
Scheme 7.a Failed synthesis of target compound 120. 
 
aReagents and conditions: a. 2.5 M n-BuLi in hexanes, anhydrous Et2O, -78 °C, 3 h; b. 
anhydrous Et2O, -29 °C, 24 h. 
 
For the third attempt, the original batch of 4-bromo-o-xylene was used as it was the one 
that produced a successful synthesis and the only variable changed between the first two 
attempts. Again, a white crystalline solid was isolated with similar Rf and chromatogram 
to compound 120, but it had a much lower melting point. This time several 
recrystallizations using absolute ethanol were attempted to further purify the white solid 
and possibly raise the melting point and produce a clean 1H NMR spectrum. The melting 
point stabilized at around 160 °C, compared to 263-264 °C for the original sample of 120. 
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The 1H NMR integrated for the number of protons that was expected for compound 120, 
but the anticipated aromatic signals were missing and instead only aliphatic protons were 
observed (other than the proton signals from the protonated amine) (Figure 30). On 
further analysis it was hypothesized that the product formed was 132 (Scheme 8). This 
was confirmed through HRMS generating a signal within 5 ppm of the theoretical 
compound (i.e., 132). A search of the literature did not yield any articles describing 
compound 132.  
 





Scheme 8.a Synthesis of off-target compound 132. 
 
aReagents and conditions: 2.5 M n-BuLi in hexanes, anhydrous Et2O, -29 °C, 24 h. 
 
After the identification of compound 132 it was established that the lithium halogen 
exchange reaction was not proceeding. Possible explanations for this reaction not taking 
place could be due to an improper amount of n-BuLi reacting either from an inaccurate 
titer from the reagent bottle due to degradation or moisture/air exposure to the reaction. 
This explanation was dismissed because compound 132 would not be able to form if this 
was the case. Another option would be to use t-BuLi for the lithium halogen exchange 
because it is an irreversible reaction but none was available at the time. Regardless, the 
lithium halogen exchange reaction should be rapid and take place for n-BuLi and reagent 
126. For the fourth and final attempt to produce target product 120 the lithium halogen 
exchange set up and reaction was meticulously monitored. Upon cooling the 4-bromo-o-
xylene (126)/anhydrous Et2O solution to -78 °C with a dry ice/acetone bath it was noted 
that a small amount of white solid was present in the flask. Testing this observation, a 
small vial was filled with a large amount of reagent 126 and anhydrous Et2O and 
submerged into the cooling bath. Solid 4-bromo-o-xylene (126) instantly precipitated from 
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solution. It would seem that the reagent was insoluble at this temperature and not taking 
part in the lithium halogen exchange reaction. A literature search revealed that 4-bromo-
o-xylene (126) melting point is -0.2 °C.86 The next step was to determine if organolithium 
reactions can safely be run at higher reaction temperatures near 0 °C and a literature 
search was successful in answering that question.87 In a study on the effects of solvent 
on lithium-bromine exchange of aryl bromides using n-BuLi at 0 °C, it was clearly shown 
that the lithium halogen exchange could safely take place with good yields at higher 
temperatures than -78 °C.87 With this knowledge the fourth attempt was continued at 0 
°C but using the same molar equivalent of n-BuLi as was used in the study by Bailey et 
al.87 (Scheme 9).  
 
Scheme 9.a Successful synthesis of target compound 120. 
 
aReagents and conditions: a. 2.5 M n-BuLi in hexanes (1.2 equiv.), anhydrous Et2O, 0 




After quenching, extraction, and purification a white crystalline solid was obtained. Just 
as in the first attempt, this compound had the same Rf and chromatogram profile for 
compound 120. The melting point was 262-264 °C matching the previously fully 
characterized target compound 120. The 1H NMR spectra displayed the anticipated 
proton signals in the aromatic region that were missing in the previous two attempts and 
integrated for the correct total number of protons (Figure 31). HRMS also confirmed the 
desired mass within 5 ppm. Target compound 120 was successfully synthesized and had 




Figure 31. 1H NMR spectrum of compound 120.  
 
The synthesis of target compound 121 followed the same procedures for the synthesis of 
compound 119 with the only difference in using 2-bromonaphthalene (127) instead of 3,4-
dichlorobromobenzene (125). This compound had a high melting point (245-247 °C) 
similar to the other two target products. 1H NMR, HRMS, and Fourier-transform infrared 
spectroscopy (FTIR) were used to characterize compound 121 (Figure 32). FTIR was 





Figure 32. 1H NMR spectrum of compound 121. 
 
b. Biological Studies 
Once each compound had been successfully synthesized and fully characterized their 
ability to inhibit DAT was examined using biological assays. The hyrbid compound 
backbone and several analogues had been previously shown to be DAT reuptake 
inhibitors and not releasing agents using a Ca2+ fluorescence assay.7 The compounds 
were evaluated as DAT reuptake inhibitors using an APP+ uptake assay. The assay was 
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performed on HEK Flp-In T-REx 293 cells stably expressing hDAT. Fluorescence 
microscopy was used to measure fluorescent intensity of the cells. APP+, which is a DAT 
substrate, fluoresces at an emission wave length of 540 nm with an excitation of 460 nm 
after transporter mediated transport intracellularly. A stepwise loss in fluroescent intensity 
is seen when the APP+ substrate is added with increasing concentrations of agents that 
interact with DAT. The potency of the test agent is in direct proportion to the inhibition of 
the fluorescence from APP+. Methylphenidate t9 and compound 119 were both used as 
standards in testing. Dose response curves (Figure 33) were obtained for the two 
standards and compounds 120 and 121 using six different concentrations (1 nM, 10 nM, 
30 nM, 100 nM, 300 nM, and 1 M) . Each concentration was repeated in triplicate and 
each experiment was repeated on separate days in order to reduce error. All data were 
analyzed using EasyRatioPro 3 and then plotted with GraphPad Prism 8.0.1. For each 
experiment 40 separate cells that showed activity were choosen as regions of interest 
(ROI). These ROIs were then used for the data to build the IC50 inhibition curves (Figure 
33). Each data set was background subtracted and normalized by the average positive 
control for the experiment day. To fill out some of the curves more completely lower and 
higher concentrations of the test compounds were used. For both compounds 119 and 
121 an extra set of experiments were performed to include concentrations of 0.1 nM and 





Figure 33. Dose-response curves of t9 and hybrid compounds 119-121 in an APP+ 
uptake assay at hDAT. 
 
The IC50 value of each compound is shown in Table 12. The potency of the standard 
methylphenidate (t9, IC50 = 70 ± 16 nM ) was similar to what had been reported previously 
(IC50 = 72 nM).7 The hybrid compound 119 was about twice as potent (IC50 = 17 ± 2.34 




Table 12. Uptake inhibition (IC50, nM) values of methylphenidate (t9) and hybrid 
compounds 119-121 in the APP+ uptake assay at hDAT.  
Compound IC50 ± SEM (nM) 
t9*                           72 
t9                           70 ± 16 
119*                           47 
119                           17 ± 2.34 
120                         379 ± 88 
121                           50 ± 25 
                           *As reported previously.7 
 
What can be seen with the new data is that all compounds are much more potent 
compared to the unsubstituted parent compound 112 (IC50 = 1080 nM).7 The dimethyl 
compound 120 was weaker (IC50 = 379 ± 88 nM) than the other two test compounds. This 
result shows that the potency of these disubstituted benzoylpiperidines is not strictly 
related to lipophilicity or occupancy of the chemical space in the binding pocket of hDAT 
but these two factors likely contribute to greater potency. The naphthyl compound 121 
with an IC50 = 50 ± 25 nM was more potent than the methylphenidate standard and had 
a similar potency to the previously published data for compound 119. The similarity in 
these two compounds’ (i.e, 119, 121) potencies demonstrate that the electron 
withdrawing character of these substituents is likely the cause for an even greater 
increase in potency from the parent compound 112 and the electron donating dimethyl 
compound 120. Also due to the high potency of compound 121 it is unlikely that 
79 
 
compound 119 is participating in halogen bonding interactions or if these interactions are 
present, they contribute minimally to its overall increased potency. However, both 119 
and 121 analogs could participate in hydrogen bond interactions via either the chloro 
substituents of compound 119 or the aromatic hydrogen atoms of compound 121. It is not 
possible with this data to state whether or not the potency of these two compounds is due 
to their electron withdrawing properties, hydrogen bonding capabilities, or a combination 
of both. To be certain of these interactions modeling and future compounds will have to 
be explored. These data correlate with the modeling data as in both instances the 
dimethyl compound 120 was the lowest scoring for modeling (see “c. Docking Studies” 
section) and had the weakest activity in the APP+ assay (see below). Compound 121 has 
a previously studied corresponding methylphenidate analog 78 with a pIC50 = 7.96. Using 
the previously developed plot of the hybrid analogs and the corresponding 
methylphenidate compounds it would be predicted that compound 121 should have a 
pIC50 = 6.60 or about 250 nM (Figure 34). The experimental pIC50 for compound 121 was 








































Figure 34. Correlation between the binding data of t9 analogs (x-axis) and APP+ uptake 
assay data (y-axis) for the corresponding methylphenidate hybrid compounds (r = 0.91, 
n = 8). Predicted pIC50 activity for compound 121 analog (red).  
 
Adding the experimental compound 121 data point to previously plotted correlation data 
increases the number of corresponding compounds to n = 9 (Figure 35). The r value 
lowers to 0.89 from 0.93 but the correlation is still statistically significant. Using this new 
plot the predicted corresponding dimethyl methylphenidate compound to the hybrid 120, 
which has not been reported, should have a binding pIC50 of approximately 7.57 (Figure 
35). What is still undetermined from these experiments are the relative potencies between 
the two possible isomers of each compound and there is still not enough data for 
disubstituted benzoylpiperidines for statistical significance. Several compounds will still 
need to be explored for an n = 6. At that point individual factors involved with the structural 









































Figure 35. Correlation between the binding data of t9 analogs (x-axis) and APP+ uptake 
assay data (y-axis) for the corresponding methylphenidate hybrid compounds (r = 0.89, 
n = 9). Predicted pIC50 binding for dimethyl t9 analog (red).  
 
c. Docking Studies 
Both S and R isomers of the three compounds 119, 120, and 121 were sketched in SybylX 
2.1.1 and energy minimized using the Tripos Force Field with Gasteiger-Hückel charges. 
Using Gold2020 each compound was docked 100 times in the hDAT homology model 
with cocaine as a reference ligand. All poses were scored with GOLD and ChemPLP. 
Gold scores for each of the isomers of the three compounds were within 1 unit of each 
other suggesting both isomers bind at the S1 central binding site of hDAT. The highest 
scoring pose for each compound were in a similar pose and had a high degree of overlap 
(Figure 36). There was not an observed difference in the rotomer orientation of D79 for 
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any of the compounds tested. Each of the S isomers was within hydrogen bond distance 
from the D79 (i.e., 2.56, 2.55, and 2.59 Å for 119, 120, and 121, respectively) while the R 
isomers were about half an angstrom too far for the desired interaction. These distances 
and scoring suggest that the S isomers of the three compounds might be more potent 
than their R isomer counterparts.  
Figure 36. hDAT homology model (cartoon, green) with possible binding poses of S 
isomer hybrids 119 (sticks, purple), 120 (sticks, cyan), and 121 (sticks, magenta). 
 
All poses generated were analyzed through HINT. Using SybylX 2.1.1 scripting language 
each pose of both S and R isomers of hybrid compounds 119, 120, and 121 was merged 
with the hDAT homology model. Each formed complex was then minimized using the 
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Tripos Force Field with Gasteiger-Hückel charges. Using Sybyl 8.1, each complex had 
the test ligand extracted into its own molecular area and HINT analysis was performed. 
For the initial partitioning phase, the dictionary method was used for the protein and the 
calculation method was used for the ligand.83,84 All other parameters were set to their 
default values. The highest scoring compound in HINT was the S isomer of hybrid 121 
(Table 13). While compound 121 was not the most potent of the series there is a good 
relationship between its high HINT score and potency. The other two compounds (i.e., 
119 and 120) had similar scores to previously docked methylphenidate (dt9). Both S and 
R isomers scored well with the S isomer of each compound scoring higher than the 
corresponding R isomer. These results suggest that all compounds are likely (and, in fact, 
were) active and that the S isomer, which has slightly better interactions within the S1 
central binding site of hDAT, is probably more potent than the R isomers. While synthesis 
and biological studies only examined the racemates of compounds 119-121, The same 
docking results could be used in future studies if the isomers are to be isolated.    
 
Table 13. HINT scores in descending order of compounds 119-121 and dt9.  
Compound HINT score 
S 121 1040 
R 121 904 
dt9 868 
S 119 842 
S 120 834 
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R 119 809 
R 120 743 
 
 
The HINT and GOLD scores do not reveal the relative potencies of the compounds. It has 
already been established that compound 119 is more potent than dt9 yet for this modeling 
study 119 scored lower for both isomers than dt9. For the potential halogen bonding 
aspect of compound 119 HINT and GOLD cannot answer this question because neither 
software takes this particular interaction into account. This could be a reason why 
compound 119 is scored lower than dt9. If a halogen bond interaction could be scored 
for either of these software packages then 119 might have the highest score. Hydrogen 
bond interactions with the substituents were not observed in the HINT analysis tables for 
compounds 119 or 121. By default, an aryl hydrogen’s partial positive charge (such as 
the aryl hydrogens on compound 121) is not considered in HINT. S149 in particular is 
aligned in such a way that the oxygen atom lone pair is in direct alignment of compound 
119’s 3-chloro substituent’s terminal end where a sigma hole would occur as well as one 
of compound 121’s aryl hydrogens from the extended phenyl ring. These atoms are within 
a distance of 3.5 Å and 3.22 Å for compounds 119 and 121, respectively. Compound 
121’s planar hydrogen atom from the extended aryl ring with its partial positive charge 
could be involved in electrostatic interactions at this distance from S149’s oxygen atom. 
There is tolerance for the large naphthyl ring mainly due to the space G153 and S149 
allows in a similar manner that is seen with the methylenedioxy ring of MDPV (10; See 
Project 2). The lowest scoring compound was compound 120. It is likely that the three 
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test compounds (119-121) scored somewhat similarly due to the hydrophobic nature of 
the substituents. Possible differences could then be due to the electron withdrawing 
character of the substituents of 119 and 121. This could be a reason why compound 121 
had the highest HINT score. The scores are too close in magnitude to make definitive 
conclusions about potency though. What these data can contribute is that all of these 
compounds more than likely should (and, in fact, did) interact with hDAT. The modeling 
allows for speculation of the actual configuration that these disubstituted compounds 
(119-121) take although it will not be proved unless either a constricted analog is 
developed that shows similar activity to the parent compounds or a crystal structure with 
one of these compounds is solved. Most likely though the structure’s substituents 
probably take the same orientations of the previous solved crystal structures of DA and 
3,4-dichlorophenethylamine in dDAT. All compounds in the modeling were likely to be 











B. Project 2. 
Aim. Evaluate binding modes of selected cathinones at DAT mutant transporters 
utilizing 3D molecular modeling 
dDAT which can be considered a natural mutant of hDAT displays unique properties for 
certain inhibitor psychostimulants. MDPV (10), -PVP (11), and MDPPP (39) have all 
been identified on the clandestine market as drugs of abuse. These three 
psychostimulants are potent hDAT inhibitors but show virtually no activity at dDAT 
(unpublished findings). With this distinction between the two species of DATs, gain-of-
function experiments were performed upon where mutating one non-conserved amino 
acid residue at a time from dDAT to hDAT, might restore activity to the three stimulants 
to what is observed in hDAT. The amino acid residues chosen for mutation were 
A117S/D121G/P323V/F318C. Three of the amino acid residues that were chosen (i.e., 
A117, P323, and F318) were those that dDAT and hSERT have conserved but are not 
present in hDAT (Figure 37). These residues are either part of, or part of the opening to, 
the S1 central binding site in dDAT and hSERT crystal structures.4,15  All three stimulants 
show no activity towards hSERT and these residues might be responsible for that lack of 
activity. The other amino acid residue D121 that was mutated was one that is unique to 
dDAT only and has been shown previously to be important for DAT inhibitor agent 
activity.15 Although several different mutants were constructed, only a triple mutant 
(A117S/D121G/P323V) and quadruple mutant (A117S/D121G/P323V/F318C) are 
considered here. The potencies of 10, 11, and 39 at these two mutants, as well as at wild-




















Figure 37. Sequence and alignment of hSERT, dDAT, and hDAT. Highlighted areas form 
the S1 central binding site and boxed amino acids are selected sites of dDAT mutations. 
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The largest increase in potency restoration contained all four-point mutations (Table 14). 
This is impressive because only four mutations were needed to see great improvement 
in functional activity. The functional data shows that the mutation of the four non-
conserved residues from hDAT into dDAT restored activity of MDPV (10) by just over 100-
fold compared to wt dDAT (Table 14; Dr. Eltit; unpublished data). Modeling studies were 
then used to compare the transporter structures and determine what molecular 
interactions were taking place between the ligands and transporters.  
 
Table 14. Potency of MDPV (10), -PVP (11), and MDPPP (39) inhibiting DA-induced 
Ca2+ signals at the indicated transporters.a 
aUnpublished data from Dr. Eltit’s lab. 
 
Construct, pIC50 ± SEM (M), (IC50 nM; # cells analyzed) 
wt dDAT triple dDAT mut quad dDAT mut wt hDAT 
MDPV 
4.56 ± 0.02 
(27,350; 437) 
5.92 ± 0.02 
(1,207; 438) 
6.60 ± 0.04 
(251; 396) 
7.47 ± 0.01 
(34; 459) 
-PVP 
4.68 ± 0.03 
(20,710; 699) 
5.82 ± 0.03 
(1,531; 599) 
5.96 ± 0.03 
(1,094; 481) 





4.80 ± 0.02 
(16,960; 551) 
4.89 ± 0.01 
(12,950; 507) 




Of all the different combinations of dDAT mutants, the four-point mutation (i.e., the 
quadruple mutant) saw the largest restoration of activity and was used for the subsequent 
modeling studies. The models used for the molecular modeling studies were the Project 
1 hDAT homology models, the available dDAT crystal structure PDB ID: 4XP4 for wt 
dDAT, and the same dDAT crystal structure as template to generate a 3D homology 
model of the quadruple (A117S/D121G/P323V/F318C) dDAT mutant. The three models 
were energy minimized using Tripos Force Field with Gasteiger-Hückel charges then 
compared using the Biopolymer suite within SybylX 2.1.1. The overall structure of these 
energy-minimized models was similar; the RMSD was 2.02 Å between hDAT and the 
quadruple dDAT mutant homology models, and 2.16 Å between hDAT and the wt dDAT 
structures. As expected, wt dDAT and the quadruple dDAT mutant models were very 
similar (RMSD = 0.29 Å). When the S1 central binding pockets were compared, the 
RMSD between hDAT and the quadruple dDAT mutant is 2.11 Å, and between hDAT and 
wt dDAT models, it was 2.12 Å. The RMSD of the binding pockets of the wt dDAT and 
quadruple dDAT mutant models was 0.36 Å. The total volume of the pockets increased 
from 2425 Å3 for wt dDAT, to 2533 Å3 for the dDAT mutant, to 3170 Å3 for hDAT. Two of 
the mutations contained residues (P323V/F318C) that were not part of the S1 central 
binding site. For docking studies this is a difficult undertaking as the test ligand is placed 
within the defined binding site to start. In reality, these mutations (P323V/F318C) might 
affect activity due to their location on the transmembrane helices and influence entry into 
the S1 site. Figure 38 shows the opening to the S1 site from the extracellular space for 















Figure 38. hDAT homology model (Connolly surface, green) with MDPV (10, sticks, 
yellow) in the S1 central binding pocket (Connolly surface, red). 
 
The S1 site is comprised of the central portions of the transmembrane helices TM1, TM3, 
TM6, and TM8.16 Helices TM3 and TM8 are uninterrupted but, helices TM1 and TM6 are 
subdivided into two helices (1a and 1b, and 6a and 6b, respectively) connected by a non-
helical segment in the middle.16 F318 and P323 are part of TM6 but they do not directly 
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face ligands. F318 is adjacent to the highly conserved F319 in the TM6a helix. F319 is 
considered the extracellular gate controlling access to the central cavity from the 
extracellular entrance.88 This gate is “open” in the outward facing conformation, and F319 
rotates to a “closed” conformation in the occluded state of the transporter.15 The F318C 
P323V mutations might influence F319 operation in such a way that it allows better access 
of the bulky MDPV molecule to the S1 site in the outward facing state through increased 
structural flexibility and manipulation of F319 positioning, this positive effect of F318C is 
less evident for the smaller -PVP (11) and MDPPP (39) molecules.  
 
For the other two mutations (A117S/D121G) that lie within the S1 binding pocket, docking 
studies were conducted to better understand potential molecular interactions with MDPV 
(10), -PVP (11), and MDPPP (39) within the three transporters. GOLD2020 was used to 
generate 100 docking solution poses of each agent in each DAT model totaling for 900 
generated poses. The S1 binding site has a composition that can be divided into three 
subsites or subpockets (A, B, and C; Figure 39) that are occupied by the terminal amine, 
aryl portion, and  side chain, respectively.15 Table 15 shows the amino acid residues 




Figure 39. Divided A, B, and C subpockets with possible binding pose of MDPV (10, 
sticks, yellow), -PVP (11, sticks, orange), and MDPPP (39, sticks, wheat) in hDAT (lines 
and cartoon, cyan) S1 central binding site. 
 
HINT analysis was used to investigate the interactions between the aromatic and alkyl 
side chains of the compounds and subpockets A, B, and C of the dDAT and hDAT 
models.84 The amino acids displayed in Table 15 were identified using the HINT analysis. 
For the initial partitioning phase, the dictionary method was used for the proteins and the 
calculation method was used for the ligands.83,84 All other parameters were set to their 
default values. In the highest scoring HINT ligand-protein complex solutions, the agents 
showed the same orientation at all three transporters (Figure 39). These poses embody 
the same 3-dimensional space in the three subpockets with the same characteristics (i.e., 
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aromatic ring, protonated nitrogen atom, and alkyl side chain) as the solved crystal 
structure pose of cocaine bound to dDAT (PDB ID: 4XP4).  
 
Table 15. Amino acid residues corresponding to the A, B, and C subpockets that make 
up the S1 central binding site in wt dDAT, dDAT (i.e., quadruple) mutant, and hDAT. 
Subpocket wt dDAT dDAT mutant hDAT 
A F43, A44, D46, 
A48, Y124, F319, 
L321, G322, S421 
F43, A44, D46, 
A48, Y124, F319, 
L321, G322, S421 
F76, A77, D79, 
A81, Y156, F320, 
L322, G323, S422 
B A117, V120, D121, 
S421, S422, G425, 
I429, Y455, S426, 
N125 
S117, V120, G121, 
S421, S422, G425, 
I429, Y455, S426, 
N125 
S149, V152, G153, 
S422, A423, G426, 
V430, T456, M427, 
N157 
C D46, V120, F319, 
F325, D475, A479, 
I483, Y123 
D46, V120, F319, 
F325, D475, A479, 
I483, Y123 
D79, V152, F320, 




HINT scores showed low scores for MDPPP (39) in all models, whereas MDPV (10) and 




Table 16. Gold and HINT scores for docking solutions of the agents MDPV (10), α-PVP 
(11), and MDPPP (39) in the wt dDAT, dDAT mutant, and hDAT models. 
Agent Transporter Gold score HINT score 
MDPV wt dDAT 58.08 376 
MDPPP wt dDAT 54.49 186 
-PVP wt dDAT 51.91 605 
MDPV dDAT mutant 58.89 261 
MDPPP dDAT mutant 54.03 342 
-PVP dDAT mutant 53.30 463 
MDPV hDAT 55.32 727 
MDPPP hDAT 52.13 287 
-PVP hDAT 51.25 759 
 
 
Each individual Interaction involving the atoms within subpockets A, B, and C with the 
three test compounds were extracted from the resulting HINT table and tabulated (Table 
17). The number of positive and negative interactions between a docked molecule at each 
protein model showed that the total favorable interactions were highest at hDAT and the 
more unfavorable interactions were highest at wt dDAT for each agent. These results are 
consistent with the functional data (Table 14). A description of the potential interaction of 
MDPV and its analogs at each subpocket (A, B, and C; Figure 39) is provided below.   
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Table 17. Tabulated positive, negative, and sum total HINT interactions of docked 
solutions for the agents MDPV (10), -PVP (11), and MDPPP (39) in the wt dDAT, dDAT 
(i.e., quadruple) mutant, and hDAT models. 





MDPV wt dDAT 8 -12 -4 
MDPV dDAT mutant 8 -9 -1 
MDPV hDAT 11 -8 3 
-PVP wt dDAT 8 -8 0 
-PVP dDAT mutant 7 -7 0 
-PVP hDAT 11 -6 5 
MDPPP wt dDAT 6 -10 -4 
MDPPP dDAT mutant 6 -8 -2 
MDPPP hDAT 11 -4 7 
 
 
a. Interactions at subpocket A 
MDPV (10), -PVP (11), and MDPPP (39) all have the same structural feature (the 
pyrrolidine ring) occupying subpocket A (Figure 40). Subpocket A had the highest scoring 
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HINT interactions compared to the other subpockets. The cause for this high score is 
driven by the salt bridge formed by the essential amino acid residue D46 (dDAT)/ D79 








Figure 40. Amino acid residues (lines) that make up subpocket A for hDAT (cyan), dDAT 
mutant (green), and wt dDAT (purple). MDPV (10, sticks, yellow) shown as a reference. 
 
b. Interactions at subpocket B  
The aromatic portion (i.e., benzodioxole or phenyl ring) of the three agents was located 
within subpocket B of the transporters (Figure 41). -PVP (11) differs from the other two 
agents in the aromatic portion of the molecules in that it lacks the methylenedioxy ring 
found in MDPV (10) and MDPPP (39). It has previously been shown that this difference 
has little effect on the potency of 11 when compared to MDPV (10) in hDAT.39 The 
influence of this methylenedioxy ring section in wt dDAT and dDAT mutant should be 
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apparent if there is a large difference between the HINT scores of -PVP (11) and the 
other two agents. Its scores were higher for all three models. This is contrary to the mutant 
transporter biological data but is likely due to fewer clashing interactions from the smaller 








Figure 41. Amino acid residues (lines) that make up subpocket B for hDAT (cyan), dDAT 
mutant (green), and wt dDAT (purple). MDPV (10, sticks, yellow) shown as a reference. 
 
hDAT had the most favorable interactions with the compounds at residues V152, S422, 
A423, G426, and M427. wt dDAT showed favorable interactions with residues V120, 
G425, I429. Two of the mutations, A117S and D121G, make up a portion of subpocket B 
and correspond to residues S149 and G153 in hDAT. These two residues have a direct 
effect on ligand/protein interactions at the S1 central binding site. The D121G dDAT single 
mutant also was the most effective at increasing MDPV’s (10) potency in the biological 
assays compared to any other dDAT single mutant evaluated (data not shown). The major 
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clashes observed in subpocket B were between the docked agents’ aryl portions and the 
residues A117 and D121 in wt dDAT. These interactions are more favorable with the 
related residues S149 and G153 in hDAT. The dDAT mutant, having the D121G mutation, 
exchanges the negative clash of the bulky aspartate residue to a positive interaction with 
the smaller neutral glycine. This allows more space for the ligand to orient and removes 
polar clashing interactions such as electronegative repulsion from the oxygen atoms of 
the methylenedioxy ring of MDPV (10) and the oxygen atoms of D121. The A117S 
mutation favors interactions with the agents by possible hydrogen bonding with one of the 
oxygen atoms of the methylenedioxy ring for MDPV (10)/MDPPP (39) and/or by bonding 
with the protein backbone, thereby increasing the size of the pocket. The measured 
distance of the potential hydrogen bond between the two methylenedioxy ring containing 
agents and the dDAT mutant and hDAT models was 3.9 Å and 7.53 Å, respectively. These 
distances make this interaction unlikely and just a weak electrostatic interaction if 
anything. If the weak but favorable interaction is occurring it would explain why that in all 
the biological data, -PVP (11) (without the methylendioxy ring) was slightly weaker than 
MDPV (10) except for the wt dDAT, which has alanine and not serine at that position. It 
was found that S117/S149 was able to form a hydrogen bond with the backbone amide 
oxygen atom of F325 or F326 in the dDAT mutant and hDAT models, respectively. The 
measured distances of these possible hydrogen bonds are 2.6 Å and 2.8 Å for the dDAT 
mutant and hDAT, respectively. The possible S117 and F325/F326 hydrogen bond would 
pull the S117/S149 residue away from the binding pocket creating more space for the 
ligand to bind. This hydrogen bond interaction cannot take place with an alanine residue 
and would explain the clashes in the wt dDAT model. The dDAT mutant did have a 
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negative interaction at G425 with the aryl portion of the agents compared to wt dDAT 
where this interaction was not observed.  
 
c. Interactions at subpocket C 
Subpocket C is enveloped with hydrophobic amino acid residues (Figure 42). The only 
nonneutral residues are the two aspartates D476/D475 and D79/D46 for hDAT and 
dDATs, respectively. The hydrophobic alkyl side chains, methyl for MDPPP (39) and n-
propyl for MDPV (10) and -PVP (11), occupied subpocket C with nothing but favorable 
hydrophobic interactions. In fact, the methyl substituent of MDPPP (39) did not have any 
overall negative interactions, only fewer favorable interactions within subpocket C 
compared to the other two compounds. In the hDAT model the α-methyl substituent of 
MDPPP (39) is not long enough to interact with residues (I484 and F155), or residues 
(I483 and A479) in the mutant and wt dDAT models, respectively. The absence of these 
interactions is most likely the driving force for why MDPPP (39) is much less potent 
compared to the other two agents MDPV (10) and -PVP (11). Due to only favorable 
interactions within subpocket C for both hDAT and dDATs, the difference in potency 
between the different transporters for MDPV (10) is plausibly not driven by its alkyl side 
chain. That is to say an extended alkyl side chain most likely benefits potency of these 
agents in DAT regardless of the construct (i.e., dDAT or hDAT) and is not responsible for 











Figure 42. Amino acid residues (lines) that make up subpocket C for hDAT (cyan), 















A two-pronged approach has provided a means in which to expand the understanding of 
DAT SAR using new compounds and “known” transporters as well as “known” 
compounds and new (i.e., mutant DAT) transporters. Through this work new hDAT 
homology models were generated, and new potent DAT inhibitors were synthesized, 
characterized, and evaluated. These projects provided insight on the types of molecular 
interactions involved in hDAT function and small molecule inhibitors for aryl substituents 
 
For project 1 a new homology model of hDAT was generated that was able to successfully 
determine that the new hybrid compounds would be active. It was found that all 
compounds tested were active in the nanomolar range exhibiting that lipophilicity () plays 
a role in DAT activity. Differences in magnitude of activity could be attributed to electronic 
character ( value) favoring electron withdrawing substituents as 3,4-dichloro compound 
119 and naphthyl compound 121 were more potent than 3,4-dimethyl compound 120. 
The volume of all the substituents are tolerated but are not the cause of difference in 
activity as compound 121 was similar in potency compared to the smaller compound 119. 
Both compounds 119 and 121 can be hydrogen bond acceptors while compound 120 
cannot. Compound 119 forming a halogen bond is not likely because 121 is almost as 
potent.  
 
For project 2 using modeling it was found that residues S149, V152, G426, and M427 
were identified to be vital interactions within the S1 central binding site. Non-conserved 
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residues identified can drive MDPV (10) selectivity not solely by stabilizing binding, but 
also controlling access to its binding site. The mutations on the outside of the binding site 
at the entrance can lend flexibility to the transporter and the overall size of the central 
binding pocket can greatly affect an agent’s activity.  
 
Modeling in both projects helped identify amino acids that are important for DAT activity 
through both SAR of small molecules and DAT mutants. Although attempts were made 
to understand the functional activity/potency of benzoylpiperdines via use of molecular 
modeling studies, it might be noted that use of radioligand binding data might have 
provided an even better picture of ligand-transporter interactions. Nevertheless, the 
current approach can be justified because the potency of methylphenidate (9) analogs as 
DAT reuptake inhibitors has been demonstrated to be significantly correlated with their 
DAT affinity as determined using radioligand binding.7 
 
Future work should include synthesis and evaluation of more disubstituted 
benzoylpiperdines as well as optical isomers to round out the SAR for the aryl portion of 
DAT inhibitors. Also, in vivo studies should be conducted to see if these compounds have 







A. Molecular Modeling 
One hundred homology models of hDAT were generated using MODELLER 9.24 and 
three crystal structures as a template.89,90 The two highest identity dDAT crystal structures 
(PDB ID: 4XPB, 4XPT) at 55.35% and 55.33% identity, respectively, as well as the 
greatest query coverage hSERT crystal structure (PDB ID: 6VRH) at 92% coverage were 
used.15,18,90 The alignment of the structures was conducted using BLAST.81 The 
sequences of both dDATs, hSERT, and hDAT were obtained from GenPept (accession 
codes 4XPB_A, 4XPT_A, 6VRH_A, and BAA22511, respectively). Due to the lack of 
corresponding residues, the first 54 residues from the N-terminus were not modelled. The 
homology model with the lowest discrete optimized protein energy (DOPE) score and 
highest GA341 score was then used for docking.89,91 GA341 is a multivariate scoring 
function that depends on compactness and combined statistical potential z-score of the 
model as well as the percentage sequence identity of the target-template alignment that 
was used to build the model.89,91 The mutant quadruple transporter in the present study 
was generated using SybylX 2.1.1 (TRIPOS Associates, Inc) by replacing the dDAT (PDB 
ID: 4XP4) amino acids with the corresponding hDAT amino acids D121G, P323V, A117S, 
and F318C.15,92 The compounds MDPV, -PVP, and MDPPP (as their S isomers) were 
sketched using SybylX 2.1.1 and energy minimized using the Tripos Force Field with 
Gasteiger-Hückel charges. The automated docking program GOLDsuite2020 was used 
to dock the three compounds one hundred times in each of the three DAT models (wt 
dDAT, quadruple dDAT mutant, hDAT) using D46 and D79 residues and the surrounding 
10-Å radius to define the binding pocket for the dDAT and hDAT models, respectively.93 
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All solutions generated from GOLD were then merged with their respective protein and 
energy-minimized using the Tripos Force Field with Gasteiger-Hückel charges in SybylX 
2.1.1.93,83 The Hydropathic INTeraction (HINT) analysis software within SYBYL 8.1 was 
used to quantify the nature and magnitude of the molecular interactions between the 
aromatic and alkyl side chains of the compounds and subpockets A, B, and C of the dDAT 
and hDAT models.84 For the initial partitioning phase, the dictionary method was used for 
the protein and the calculation method was used for the ligands.83,84 All other parameters 
were set to their default values. Atom-based interactions involving atoms within 
subpockets A, B, and C were extracted from the resulting HINT table and tabulated. 
MOLCAD and BioPolymer suite within SybylX 2.1.1 were used for binding pocket volume 
calculations and RMSD calculations, respectively. 
 
B. Synthesis 
Melting points were taken on MEL TEMP melting point apparatus in glass capillary tubes 
and are uncorrected. 1H NMR spectra were recorded using a Bruker AXR 400 MHz 
spectrometer with tetramethylsilane (TMS) as an internal standard. Signal positions are 
given in parts per million (δ) downfield from TMS, together with their splitting pattern (s = 
singlet, d = doublet, t = triplet, q = quartet, dd = doublet of doublets, m = multiplet), 
coupling constant (J, Hz) and integration. MS were recorded using a Waters Acquity 
tandem quadrupole (TQD) instrument with electrospray ionization. Infrared spectra were 
obtained on a Thermo Nicolet iS10 FT-IR spectrophotometer. Microanalyses were 
performed by Atlantic Microlab Inc. (Norcross, GA) for the indicated elements and results 
are within 0.4% of calculated values. Reactions were routinely monitored by thin-layer 
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chromatography (TLC) using silica gel GHLF plates (250 mm, 2.5 x 10 cm; Analtech Inc. 
Newark, DE), and flash chromatography was performed on a CombiFlash Companion/TS 
(Teledyne Isco Inc. Lincoln, NE). All final compounds were prepared as water-soluble 
hydrochloride salts.  
 
2-(3,4-Dichlorobenzoyl)piperidine Hydrochloride (119). 1-Bromo-3,4 dichlorobenzene 
(125; 0.50 g, 2.2 mmol) was dissolved in anhydrous Et2O (7 mL) under an N2 atmosphere 
and cooled to -78 °C (acetone : dry ice) and then 2.5 M n-BuLi in hexane (1.8 mL, 4.4 
mmol) was added in a dropwise manner over 15 min. The reaction mixture was stirred at 
-78 °C for 3 h to give intermediate 128. In another flask a stirred solution of 124 (0.59 g, 
2.2 mmol) in Et2O (5 mL) under an N2 atmosphere was cooled to -29 °C (o-xylene : dry 
ice) and then 128 was added in a dropwise manner over 15 min. The reaction mixture 
was stirred at -29 °C for 3 h and allowed to warm to room temperature with continued 
stirring for 12 h. The reaction mixture was quenched using cold 1 M KH2PO4 (20 mL), 
extracted with EtOAc (3 x 30 mL), dried over MgSO4, filtered, and evaporated under 
reduced pressure to produce a yellow oil that was chromatographed on silica gel 10 : 0 – 
7 : 3 hexane : EtOAc. The collected fractions were combined and concentrated under 
reduced pressure. The concentrate was dissolved in anhydrous Et2O and cooled in an 
ice bath. Anhydrous methanolic HCl was added in a dropwise manner until pH=1. The 
solution was stirred overnight and evaporated to dryness. Washing with acetone then 
recrystallization from MeOH gave 0.07 g of 119 as a white solid (12% yield): mp 272-273 
°C (lit.7 mp 273-275 °C); 1H NMR (DMSO-d6 , 400 Mhz) δ 1.42–1.45 (m, 1H, CH2), 1.65–
1.77 (m, 4H, 2 x CH2), 2.06–2.09 (d, 1H, J = 12 Hz, CH2), 2.92–2.95 (d, 1H, J = 12 Hz, 
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CH2), 3.33–3.36 (d, 1H, J = 12 Hz, CH2), 5.13–5.18 (m, 1H, CH), 7.89-7.92 (m, 1H, Ar-
H), 8.01–8.03 (m, 1H, Ar-H), 8.30–8.31 (m, 1H, Ar–H), 8.97-8.98 (br d, 1H, NH), 9.53-
9.64 (br d, 1H, NH+); IR (diamond, cm–1) 1685 (C═O); HRMS (ESI-TOF) m/z [M + H]+ 
calcd for C12H13NOCl2, 258.0452; found, 258.0439; Anal. Calcd for C12H13NOCl2·HCl: C, 
48.92; H, 4.79; N, 4.75. Found: C, 48.81; H, 4.80; N, 4.77. 
 
2-(3,4-Dimethylbenzoyl)piperidine Hydrochloride (120). 4-Bromo-o-xylene (126; 0.35 
mL, 2.6 mmol) was dissolved in anhydrous Et2O (5 mL) under an N2 atmosphere and 
cooled to 0 °C (ice-bath) and then 2.5 M n-BuLi in hexane (1.3 mL, 3.1 mmol) was added 
in a dropwise manner over 15 min. The reaction mixture was stirred at 0 °C (ice bath) for 
3 h to give intermediate 129. In another flask a stirred solution of 124 (0.20 g, 1.8 mmol) 
in Et2O (5 mL) under an N2 atmosphere was cooled to -29 °C (o-xylene : dry ice) and then 
129 was added in a dropwise manner over 15 min. The reaction mixture was stirred at -
29 °C for 3 h and then allowed to warm to room temperature with continued stirring for 12 
h. The reaction mixture was quenched using cold 1 M KH2PO4 (25 mL), extracted with 
EtOAc (3 x 30 mL), dried over Na2SO4, filtered, and evaporated under reduced pressure 
to produce a yellow oil that was chromatographed on silica gel 9.5 : 0.5 hexane : EtOAc. 
The collected fractions were combined and concentrated under reduced pressure. The 
concentrate was dissolved in anhydrous MeOH and cooled in an ice-bath. Anhydrous 
methanolic HCl was added in a dropwise manner until pH=1. The solution was stirred 
overnight and evaporated to dryness. Washing with acetone then recrystallization from 
EtOH gave 0.12 g of 120 as a white solid (27% yield): mp 262-264 °C; 1H NMR (DMSO-
d6, 400 Mhz) δ 1.48(m, 1H, CH2), 1.82(m, 4H, 2 x CH2), 2.11(d, 1H, J = 16 Hz, CH2), 
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2.38(s, 6H, 2 x CH3), 3.01(d, 1H, J = 12 Hz, CH2), 3.40(d, 1H, J = 16 Hz, CH2), 5.11(m, 
1H, CH), 7.42(m, 1H, ArH), 7.85(m, 1H, ArH), 7.89(s, 1H, ArH), 8.94(br s, 1H, NH), 9.81(br 
s, 1H, NH+); IR (diamond, cm–1) 1683 (C═O); HRMS (ESI-TOF) m/z [M + H]+ calcd for 
C14H19NO, 218.1545; found, 218.1536. 
 
2-(Naphtho-2-yl)piperidine Hydrochloride (121). 2-Bromonaphthalene (127; 0.50 g, 
2.43 mmol) was dissolved in anhydrous Et2O (10 mL) under an N2 atmosphere. The 
stirred mixture was cooled to -78 °C (acetone : dry ice). n-BuLi in hexanes (2.5 M, 5.93 
mL, 4.83 mmol) was added in a dropwise manner over 15 min. The reaction mixture was 
stirred at -78 °C for 3 h to give intermediate 130. In another flask a stirred solution of 124 
(0.62 g, 2.74 mmol) in Et2O (5 mL) under an N2 atmosphere was cooled to -23 °C (CCl4 : 
dry ice bath). Compound 130 was added in a dropwise manner over 15 min. The reaction 
mixture was stirred at -23 °C (CCl4 : dry ice bath) for 3 h and then allowed to warm to 
room temperature with continued stirring for 12 h. The reaction mixture was quenched 
using cold 1 M KH2PO4 (20 mL), extracted with EtOAc (3 x 30 mL), dried over MgSO4, 
filtered, and evaporated under reduced pressure to produce a yellow oil that was 
chromatographed on silica gel 10 : 0 – 2 : 8 hexane : EtOAc. The collected fractions were 
combined and stirred in anhydrous methanolic HCl overnight and evaporated to dryness. 
Recrystallization from MeOH gave 0.13 g of 121 as a white solid (20% yield): mp 245-
247 °C; 1H NMR (DMSO-d6, 400 Mhz) δ 1.49–1.59 (q, 1H, CH2), 1.73–1.89 (m, 4H, 2 x 
CH2), 2.19–2.23 (d, 1H, J = 16 Hz, CH2), 3.00–3.06 (t, 1H, J = 12 Hz, CH2), 3.34–3.40 (t, 
1H, J = 12 Hz, CH2), 5.27–5.30 (d, 1H, J = 12 Hz, CH), 7.67-7.76 (m, 2H, Ar-H), 8.03–
8.07 (m, 2H, Ar-H), 8.10–8.13 (d, 1H, J = 12 Hz, Ar–H), 8.17–8.19 (d, 1H, J = 8 Hz, Ar–
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H), 8.85 (s, 1H, Ar–H), 9.00 (br s, 1H, NH), 9.86 (br s, 1H, NH+); IR (diamond, cm–1) 1674 
(C═O); HRMS (ESI-TOF) m/z [M + H]+ calcd for C16H18NO, 240.1383; found, 240.1374. 
 
N-Boc-pipecolic acid (123). Pipecolic acid (122) (2.0 g, 15.5 mmol) was added to MeOH 
(22 mL) followed by the addition of Et3N (2.4 mL, 17.2 mmol). Room temperature (Boc)2O 
(7.12 mL, 31.0 mmol) was then added to the stirred reaction mixture via syringe. The 
reaction mixture was stirred for 1 h at room temperature. The mixture was then 
concentrated under reduced pressure and suspended between EtOAc (75 mL) and sat. 
NaHCO3 (75 mL). The organic layer was extracted with sat. NaHCO3 (2 x 30 mL) and 
H2O (30 mL). The aqueous portions were combined and brought to pH 2 using 3 M HCl 
and extracted with EtOAc (4 x 30 mL). The combined organic portion was dried over 
MgSO4, filtered, and evaporated under reduced pressure to yield 3.4 g of N-Boc-2-
pipecolic acid (123) as a white solid (95% yield): mp 130-133 °C. (lit.67 123-124 °C). 
 
N-Boc-pipecolate N-(methylmethoxyl)amide (124). N-Boc-2-pipecolic acid (123; 3.38 
g, 14.7 mmol) was dissolved in DCM (50 mL) followed by the addition of N,O-
dimethylhydroxylamine hydrochloride (1.72 g, 17.7 mmol) and Et3N (7.18 mL, 51.5 mmol). 
BOP (7.16 g, 16.2 mmol) was then added and the mixture was stirred at room temperature 
for 16 h. The reaction mixture was then diluted with DCM (150 mL) and added to a 
separatory funnel containing 1 M HCl (75 mL). The organic layer was washed with sat. 
NaHCO3 (3 x 30 mL), brine (2 x 30 mL), H2O (2 x 30 mL), and 5% HCl (2 x 30 mL), dried 
over MgSO4, filtered, and evaporated under reduced pressure. The resultant oil was then 
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chromatographed on silica gel 4 : 1 hexanes : EtOAc to give 3.35 g of 124 as a colorless 
oil that crystallized to a white solid over 48 h (84% yield): mp 64-66 °C (lit.94 66-68 °C). 
 
2-(1-Pentoyl)piperidine Hydrochloride (132) 4-Bromo-o-xylene (126; 0.35 mL, 2.6 
mmol) was dissolved in anhydrous Et2O (5 mL) under an N2 atmosphere and cooled to -
78 °C (acetone : dry ice) and then 2.5 M n-BuLi in hexane (2.08 mL, 5.2 mmol) was added 
in a dropwise manner over 15 min. The reaction mixture was stirred at -78 °C for 3 h to 
give intermediate 128. In another flask a stirred solution of 124 (0.57 g, 2.6 mmol) in Et2O 
(5 mL) under an N2 atmosphere was cooled to -29 °C (o-xylene : dry ice) and then 128 
was added in a dropwise manner over 15 min. The reaction mixture was stirred at -29 °C 
for 3 h and allowed to warm to room temperature with continued stirring for 12 h. The 
reaction mixture was quenched using cold 1 M KH2PO4 (20 mL), extracted with EtOAc (3 
x 30 mL), dried over MgSO4, filtered, and evaporated under reduced pressure to produce 
a yellow oil that was chromatographed on silica gel 10 : 0 – 7 : 3 hexane : EtOAc. The 
collected fractions were combined and concentrated under reduced pressure. The 
concentrate was dissolved in anhydrous Et2O and cooled in an ice bath. Anhydrous 
methanolic HCl was added in a dropwise manner until pH=1. The solution was stirred 
overnight and evaporated to dryness. Washing with acetone then recrystallization from 
MeOH gave 0.13 g of 132 as a white solid: mp 162-163 °C; 1H NMR (DMSO-d6 , 400 
Mhz) δ 0.87 (s, 3H, CH3), 1.26–1.28 (m, 2H, CH2), 1.48–1.68 (m, 7H, CH2), 2.21–2.24 
(m, 1H, CH2), 2.59 (m, 1H, CH2), 2.78-2.84 (m, 1H, CH), 3.19 (d, 1H, J = 12 Hz, CH2), 
4.01-4.04 (dd, 1H, J = 12 Hz, CH), 9.22-9.28 (br s, 1H, NH), 9.22-9.28 (br s, 1H, NH+); 




C. APP+ Uptake Assay 
1. Preparation of HEK293 cells 
A HEK293 Flp-In T-REx cell line stably expressing hDAT was developed previously in the 
laboratory.46 Cells were prepared in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% fetal bovine serum and hygromycin. The cells were plated on 96-
well plates and were transiently transfected with red fluorescent protein (DsRed, TaKaRa 
Bio USA, Mountain View, CA) which is used to focus cells to a monolayer plane in the 
fluorescence microscope before the addition of APP+. Doxycycline (1 g/mL) was added 
to the culturing media 3 days before the experiment to induce expression of DAT. 
 
2. Solution for the experiment 
Imaging solution (IS) was prepared and was used to dissolve all the analogs and as a 
vehicle. It consisted of NaCl (130 mM), KCl (4 mM), CaCl2 (2 mM), MgCl2 (1 mM), Hepes 
(10 mM), and glucose (10 mM). The pH of the IS was adjusted between 7.3-7.4 using a 
saturated solution of NaOH. 
 
3. Agents 
threo-Methylphenidate was purchased as its hydrochloride salt from 
Sigma-Aldrich, St. Louis, MO. 
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4. Live-cell imaging 
The cells were placed on the stage of the epifluorescent microscope (Olympus IX71) 
equipped with a light source DeltaRAM X Random Access Monochromator (HORIBA 
Scientific, Piscataway, New Jersey), a Lightning-Cam camera (HORIBA Scientific, 
Piscataway, New Jersey), and an automated perfusion system Pressurized Superfusion 
(AutoMate Scientific, Berkeley, California) regulated by Clampex 10.2 (Molecular 
Devices, San Jose, California). The imaging system was coordinated using the 
EasyRatioPro 3 (HORIBA Scientific, Piscataway, New Jersey). The entire experiment 
was done at room temperature. The DsRed signal of transfected cells were used to find 
the focal plane of the cell monolayer. The wavelength of 460 nm was used for excitation 
of the APP+ and 540 nm to detect the emission. The experiment consisted of three 
phases over 70 seconds and was under constant perfusion. The cells were exposed with 
the IS for 10 seconds followed by the compound of interest for 30 seconds and finally 
compound of interest plus APP+ (3 μM) for 30 seconds. All the hybrid analogs were 




The data obtained from the APP+ assay were analyzed using EasyRatioPro 3 (HORIBA 
Scientific, Piscataway, New Jersey) and the dose-response curves were plotted using 
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